Document:

EX-10.1

 Exhibit 10.1 

Confidential Treatment Requested by Sienna Biopharmaceuticals, Inc. 

AMENDED AND RESTATED 

EXCLUSIVE SUPPLY AND LICENSE AGREEMENT 

by and between 
 NANOCOMPOSIX,
INC. 
 a California Corporation 

and 
 SIENNA BIOPHARMACETICALS,
INC. 
 a Delaware corporation 

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for 

confidential treatment and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested by Sienna Biopharmaceuticals, Inc. 

 

 AMENDED AND RESTATED 

EXCLUSIVE SUPPLY AND LICENSE AGREEMENT 

This Amended and Restated Exclusive Supply and License Agreement (“Agreement”) is made as of April 19, 2017 (the
“Restatement Date”), by and between Sienna Biopharmceuticals, Inc. (formerly Sienna Labs, Inc.), a Delaware corporation, with its principal place of business at 30699 Russell Ranch Road, Suite 140, Westlake Village, CA 91362
(“SIENNA”), and NANOCOMPOSIX Inc., a California corporation, with its principal place of business at 4878 Ronson Court, Suite K, San Diego, CA 92111 (“NANOCOMPOSIX”). SIENNA and NANOCOMPOSIX may be referred to
individually as a “Party” or collectively as the “Parties.” 
 RECITALS 

WHEREAS, NANOCOMPOSIX manufactures certain nanoparticle based Materials (as defined herein) and is the owner of certain patent rights and
technology relating to such Materials; 
 WHEREAS, SIENNA desires to obtain exclusive supply of such Materials for use in the Field (as
defined below) and a license under the Materials and patent rights of NANOCOMPOSIX for commercial applications of such Materials in the Field, all upon the terms and conditions hereinafter set forth; 

WHEREAS, in furtherance of the foregoing, the Parties entered into an Exclusive Supply and License Agreement, dated July 21, 2011 (the
“Original Agreement”), which was amended and restated in its entirety most recently on August 4, 2015 (the “Restated Agreement”); and 

WHEREAS, the Parties now desire to enter into this Agreement for the purpose of superseding and replacing in their entirety the Restated
Agreements. 
 NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the
receipt and adequacy of which are hereby acknowledged, effective as of the Restatement Date, the Parties hereby agree as follows: 

ARTICLE 1 

DEFINITIONS 
 1.1
“Affiliate” shall mean any person or entity who directly or indirectly controls or is controlled by or is under common control with a Party to this Agreement, where “control” or “controlled” means ownership,
directly or through one or more Affiliates, of fifty percent (50%) or more of the shares of stock entitled to vote for the election of directors, in the case of a corporation, or fifty percent (50%) or more of the equity interest, in the case of any
other type of legal entity, or status as a general partner in any partnership, or the contractual right to control the election of directors or direct the affairs of such Party. 

1.2 “Combination Product” shall mean any kit sold by SIENNA or its Affiliate or Sublicensee containing one or more components
that, if sold as stand-alone items, would constitute Licensed Products and other separate components that, if sold as stand-alone items, would not constitute Licensed Products`. 

1.3 “Confidential Information” means any and all information provided by one Party to the other Party, either directly or
indirectly, whether in graphic, written, electronic or oral form, identified at 

  
 Confidential Portions
of this Exhibit marked as [***] have been omitted pursuant to a request for 
 confidential treatment and have been filed separately with the
Securities and Exchange Commission. 

  
 2 

 Confidential Treatment Requested by Sienna Biopharmaceuticals, Inc. 

 

 
the time of disclosure as confidential, or which by its context would reasonably be deemed to be confidential, including without limitation all trade secrets, processes, formulae, data, know-how, improvements, inventions, chemical or biological materials, techniques, marketing plans, strategies, customer lists, or other information (including all information and materials of a Party’s
customers and any other third party and their consultants). Without limiting the foregoing, the Materials and all information and data relating to the Materials constitutes NANOCOMPOSIX’S Confidential Information to the extent not disclosed or
described in the Patent Rights. 
 1.4 “Effective Date” shall mean July 21, 2011. 

1.5 “Field” shall mean all medical, veterinary, aesthetic and cosmetic uses of the Materials in conjunction with an
[***], including without limitation for the purposes of diagnosis, prevention or treatment of any disease, state or condition in humans or animals, and aesthetic and cosmetic uses. 

1.6 “First Commercial Sale” means, on a
country-by-country basis, the date of the first arm’s length transaction, transfer or disposition for value of a Licensed Product by or on behalf of SIENNA or any
Affiliate or Sublicensee to a third party. 
 1.7 “Licensed Product” shall mean any product (i) using, incorporating,
or otherwise containing the Materials, in all forms, presentations, formulations and dosage forms, and/or (ii) that the manufacture, use, sale, offer for sale or import of which, but for the license granted to SIENNA herein, would infringe a
Valid Claim of the Patent Rights. 
 1.8 “Materials” shall mean the Materials set forth in
Exhibit A, whether by themselves or incorporated into or combined with another Material, and all modifications, copies and derivatives thereof, and all improvements to such Materials, whether made by or for NANOCOMPOSIX,
SIENNA, its Affiliates, and/or any third party. Exhibit A may be amended upon the written agreement by the Parties. 

1.9 “Net Sales” shall mean the gross amount collected by SIENNA and its Affiliates and Sublicensees for sales or other
transfers of Licensed Products, less the following: 
 (a) customary trade, quantity, or cash discounts to the extent actually allowed and
taken; 
 (b) amounts repaid or credited by reason of rejection or return; 

(c) to the extent separately stated on purchase orders, invoices, or other documents of sale, any taxes or other governmental charges levied
on the sale of a Licensed Product which is paid by or on behalf of SIENNA or its Affiliate or Sublicensee; and 
 (d) outbound
transportation costs prepaid or allowed and costs of insurance in transit to the extent separately stated on purchase orders, invoices or other documents of sale. 

For the avoidance of doubt, transfer of a Licensed Product among any of SIENNA, its Affiliates or its Sublicensees shall not be considered Net
Sales hereunder but in such cases the royalty shall be due and calculated upon SIENNA, its Affiliate’s or Sublicensee’s Net Sales of Licensed Product to the first independent third party, which may include any distributors of SIENNA. 

  
 Confidential Portions
of this Exhibit marked as [***] have been omitted pursuant to a request for 
 confidential treatment and have been filed separately with the
Securities and Exchange Commission. 

  
 3 

 Confidential Treatment Requested by Sienna Biopharmaceuticals, Inc. 

 

 In the event that a Licensed Product is sold as a Combination Product, Net Sales, for the
purposes of determining royalty payments on the Combination Product, shall mean, on a country-by-country basis, the gross amount collected for the Combination Product
less the deductions set forth in clauses (a)–(d) above, multiplied by a proration factor that is determined as follows: 

(i) If all components of the Combination Product (including the Licensed Product component) were sold separately during the
same or immediately preceding Reporting Period, the proration factor shall be determined by [***], where A is [***] during such period when sold separately from the other component(s), and B is [***] during such period when sold
separately from the Licensed Product components; or 
 (ii) If all non-Licensed
Product components of the Combination Product were not sold or provided separately during the same or immediately preceding Reporting Period, the proration factor shall be determined by [***] where A shall have the value [***], and B
shall be equal to [***] to SIENNA or its Affiliate or Sublicensee (as applicable) for the [***], multiplied by [***] percent ([***]%). 

1.10 “Patent Rights” shall mean: 

(a) the United States and international patents listed on Exhibit B; 

(b) the United States and international patent applications and provisional applications listed on Exhibit B; 

(c) any other patent application or patent heretofore or hereafter filed or having legal force in any country within the Territory which claim
the Materials, or the process of manufacture or use thereof; 
 (d) any patent applications claiming priority from the patent applications
described in clauses (b) and (c) above, and any direct or indirect divisionals, continuations, continuation-in-part applications, and continued prosecution
applications (and their relevant international equivalents) of the patent applications described in clauses (b) and (c) above and of such patent applications claiming priority from the patent applications described in clauses (b) and (c)
above, to the extent the claims are directed to subject matter specifically described in patent applications described in clauses (b) and (c) above, and the resulting patents; 

(e) any patents resulting from reissues, reexaminations, or extensions (and their relevant international equivalents, including, without
limitation supplementary protection certificates) of the patents described in clauses (a), (b) (c) and (d) above; and 
 (f)
international (non-United States) patent applications and provisional applications filed after the Effective Date and the relevant international equivalents to divisionals, continuations, continuation-in-part applications and continued prosecution applications of the patent applications to the extent the claims are directed to subject matter specifically
described in the patents or patent applications referred to in clauses (a), (b), (c), (d) and (e) above, and the resulting patents. 

1.11 “Prior Restatement Date” shall mean August 4, 2015. 

1.12 “Reporting Period” shall begin on the first day of each calendar quarter and end on the last day of such calendar
quarter. 

  
 Confidential Portions
of this Exhibit marked as [***] have been omitted pursuant to a request for 
 confidential treatment and have been filed separately with the
Securities and Exchange Commission. 

  
 4 

 Confidential Treatment Requested by Sienna Biopharmaceuticals, Inc. 

 

 1.13 “Sublicense Revenue” shall mean all [***] payments received by
SIENNA or its Affiliates in consideration for the grant of a sublicense under the Patent Rights under Section 3.2, including any upfront payments, license maintenance fees, milestone payments or the like, subject to the following: Sublicense
Revenue will not include (a) amounts paid [***], (b) amounts received [***], (c) amounts received [***] the Restatement Date, (d) amounts received by SIENNA [***], including without limitation [***] (it
being understood that SIENNA will pay to NANOCOMPOSIX [***] (as described in Section [***])), (e) amounts received by SIENNA [***] of SIENNA, or [***] of SIENNA, except to the extent any [***], (f) amounts received
for [***] the Restatement Date, (g) amounts received that are related to Licensed Product [***], [***], and/or [***], including without limitation any amounts received [***] of Licensed Products or components
thereof for [***], (h) amounts received [***] by SIENNA of any [***], (i) [***], (j) amounts received pursuant to a sale of substantially all of the stock, business or assets of SIENNA (in each case, whether by merger,
sale of stock, sale of assets or otherwise) [***], or (k) amounts that are otherwise not attributable to the grant of a sublicense under the Patent Rights and/or Materials. Sublicense Revenue excludes [***] ([***]) and
payments by sublicensee for [***], [***], [***] and [***]. 
 1.14 “Sublicensee” shall mean any
non-Affiliate sublicensee of the rights granted by SIENNA pursuant to Section 3.2. For clarity, “Sublicensee” shall not include any contract research organization, contract manufacturing
organization, wholesaler or distributor of SIENNA. 
 1.15 “Term” shall mean the term of this Agreement, which shall
commence on the Effective Date and shall remain in effect until the later of (i) ten (10) years or (ii) expiration or abandonment of all Valid Claims within the Patent Rights, in each case unless earlier terminated in accordance with the
provisions of this Agreement. 
 1.16 “Territory” shall mean the entire world. 

1.17 “Valid Claim” shall mean (a) a claim of an issued and unexpired patent which has not been revoked or held
unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and which has not been admitted to be invalid or unenforceable through reissue
or disclaimer or otherwise, or (b) a claim of a pending patent application that was filed and has been prosecuted in good faith and has not been (i) cancelled, withdrawn, abandoned or finally disallowed without the possibility of appeal or
refiling of such application, or (ii) pending for more than [***] ([***]) years since such claim was first presented or is the result of amending another claim pending for more than [***] ([***]) years (either in the
same application or in another application in the same jurisdiction) so as to add or delete an obvious limitation, so as to make a trivial or nonsubstantive change, or so as to change a matter of form. 

ARTICLE 2 

EXCLUSIVE PURCHASE AND SUPPLY 

2.1 Exclusive Purchase and Supply. SIENNA hereby retains and appoints NANOCOMPOSIX as its and its Affiliates’ and
Sublicensees’ exclusive supplier of Materials, and of all materials similar to the Materials, in either case for use in the Field as permitted herein during the Supply Term (as defined below), and NANOCOMPOSIX hereby accepts such retention and
appointment in accordance with the terms of this Agreement. Subject to SIENNA’S compliance with the terms of this Agreement, NANOCOMPOSIX hereby represents that during the Term it shall not [***] supply, provide or otherwise distribute
Materials to third parties for use in the Field. NANOCOMPOSIX is [***] before selling Materials to customers. If NANOCOMPOSIX becomes aware that an end user is using Materials in the Field, then it will promptly notify SIENNA of the same and
will not directly supply, [***] 

  
 Confidential Portions
of this Exhibit marked as [***] have been omitted pursuant to a request for 
 confidential treatment and have been filed separately with the
Securities and Exchange Commission. 

  
 5 

 Confidential Treatment Requested by Sienna Biopharmaceuticals, Inc. 

 

 
Materials to such end user until NANOCOMPOSIX has received written confirmation that such end user will not use the Materials in the Field. If NANOCOMPOSIX becomes aware that Materials are being
purchased by an end user for use in the Field through one of NANOCOMPOSIX’S distributors, then NANOCOMPOSIX will promptly notify SIENNA of the same and will promptly instruct such distributor not to supply such end user with Materials until
such distributor has received written confirmation that such end user will not use the Materials in the Field. As used herein, the “Supply Term” shall commence upon the Effective Date and expire upon the later of
(i) SIENNA’S [***] of Licensed Products in the Field, or (ii) [***] years from the Prior Restatement Date. 

2.2 Supply Terms. NANOCOMPOSIX agrees that, during the Term, it will supply the Materials to SIENNA for use in the Field, which supply
is subject to the terms and conditions of this Agreement, including those set forth on Exhibit C. The Parties further agree that no later than [***] ([***]) months prior to the anticipated First Commercial Sale of a Licensed
Product, the Parties will initiate good faith negotiations to enter into a commercial supply agreement (the “Commercial Supply Agreement”) incorporating such terms and conditions, in addition to those set forth on Exhibit C,
as are usual and customary for a commercial supply arrangement. 
 2.3 Inspection. To the extent required by applicable law, and upon
at least [***] ([***]) days notice and no more than [***] per year, SIENNA LABS may inspect any of NANOCOMPOSIX’s facilities and operations to inspect NANOCOMPOSIX production and supply of Materials for SIENNA LABS. All of
SIENNA LABS’ observations and information received in performing such inspection shall be NANOCOMPOSIX Confidential Information. 

ARTICLE 3 
 GRANT OF
RIGHTS 
 3.1 License Grant and Restrictions. 

(a) Subject to the terms and conditions of this Agreement, NANOCOMPOSIX hereby grants to SIENNA and its Affiliates for the Term a
royalty-bearing, exclusive license, with the right to sublicense as provided in Section 3.2, under the Patent Rights, to make, have made, use, have used, sell, have sold, offer to sell, have offered for sale, import and have imported Licensed
Products in the Field in the Territory. 
 (b) NANOCOMPOSIX acknowledges and agrees that, during the Term, it shall not directly or
indirectly grant any licenses or other rights inconsistent with this Agreement, including this Section 3.1 and Exhibit C. 
 (c)
Notwithstanding Section 3.1(a), except as set forth in Exhibit C, SIENNA and its AFFILIATES and Sublicensees may not otherwise (i) make or have made Materials; (ii) reproduce or duplicate Materials; or (iii) modify the
structure of the Materials. 

  
 Confidential Portions
of this Exhibit marked as [***] have been omitted pursuant to a request for 
 confidential treatment and have been filed separately with the
Securities and Exchange Commission. 

  
 6 

 Confidential Treatment Requested by Sienna Biopharmaceuticals, Inc. 

 

 3.2 Sublicenses. SIENNA shall have the right to grant sublicenses (through multiple
tiers) under the license granted to SIENNA in Section 3.1 and under any license granted to SIENNA under Exhibit C. The terms of each sublicense shall not conflict with, and shall be subordinate to, the terms and conditions of this
Agreement, and each sublicense shall contain provisions substantially equivalent to Article 4, Article 5, Article 12 and Article 13 and Sections 3.1, 3.3, 3.4 and 9.2, and may not abrogate or diminish the terms of this
Agreement or NANOCOMPOSIX’S rights. SIENNA shall be responsible to collect from its Sublicensees royalties on Net Sales by Sublicensees due under Section 4.1 and to remit such royalties to NANOCOMPOSIX. SIENNA shall furnish NANOCOMPOSIX
with a copy (which may be redacted with respect to [***]) of each fully signed sublicense agreement within [***] ([***]) days of its execution. Upon termination of this Agreement for any reason, and provided that (i) SIENNA
has first represented and warranted to NANOCOMPOSIX that, to SIENNA’s actual knowledge, as of the effective date of such termination, a Sublicensee is then in full compliance with all terms and conditions of its sublicense and this Agreement,
(ii) all accrued payment obligations to NANOCOMPOSIX hereunder have been paid, and (iii) the Sublicensee agrees in writing to assume all applicable obligations of SIENNA under this Agreement, NANOCOMPOSIX shall grant to such Sublicensee
license rights and terms equivalent to the license granted to SIENNA herein in a separate written agreement. 
 3.3 No Contest of
Patents. If SIENNA or its Affiliate or Sublicensee initiates or voluntarily joins as a party to any legal action which challenges the validity or enforceability of the Patent Rights or any claim therein, or NANOCOMPOSIX’S title thereto,
then NANOCOMPOSIX may terminate this Agreement upon notice to SIENNA. 
 3.4 Reservation of Rights. As between the Parties,
NANOCOMPOSIX shall solely and exclusively own all right, title and interest in and to the Patent Rights and the Materials. All rights or licenses not expressly granted hereunder are reserved by each Party and no implied licenses are granted to
either Party under this Agreement. 
 ARTICLE 4 

ROYALTIES AND PAYMENT TERMS 

4.1 Running Royalties. On a product-by-product and country-by-country basis, SIENNA shall pay NANOCOMPOSIX [***] percent ([***]%) of Net Sales of Licensed Products made, sold, transferred or imported by SIENNA,
its Affiliates and Sublicensees from the First Commercial Sale of a particular Licensed Product in a country until the later of: (i) five (5) years after the First Commercial Sale in such country and (ii) the expiration of the last to
expire patent within the Patent Rights in such country where such manufacture, sale, transfer or import then infringes any Valid Claims covering the Licensed Product. Running royalties shall be payable for each Reporting Period and shall be due to
NANOCOMPOSIX within [***] ([***]) days of the end of each Reporting Period. For clarity, the royalties on Net Sales by Sublicensees shall be payable by SIENNA within [***] ([***]) days after the end of the Reporting
Period in which such royalties are collected by SIENNA from the Sublicensees. During the Term, in the event the royalties paid by SIENNA under Section 4.1 on Net Sales of Licensed Products do not amount to a Minimum Royalty Payment of at least
Fifty Thousand Dollars ($50,000) in any year after 2015, then SIENNA shall, at the time of making the royalty payment for the last Reporting Period of such year, pay NANOCOMPOSIX an amount equal to the difference between the Minimum Royalty Payment
and the royalties paid by SIENNA under Section 4.1 for such year. 
 (a) Royalty Stacking. To the extent that SIENNA or any of
its Affiliates or Sublicensee obtains licenses to third party patent rights or other intellectual property in order to manufacture, use, or sell any Licensed Products, then SIENNA , its Affiliate or Sublicensee (as

  
 Confidential Portions
of this Exhibit marked as [***] have been omitted pursuant to a request for 
 confidential treatment and have been filed separately with the
Securities and Exchange Commission. 

  
 7 

 Confidential Treatment Requested by Sienna Biopharmaceuticals, Inc. 

 

 
applicable) may on a product-by-product and
country-by-country basis, reduce the royalty rate applicable hereunder for any Licensed Products in which such licenses were necessary by [***] percent
([***]% ) for each [***] percent ([***]%) of royalty rate payable to such third party (without taking into account the third party’s royalty reduction provision with similar intent to this Section); provided, however, that
in no event will the royalty rate otherwise due to NANOCOMPOSIX be reduced to less than [***] percent ([***]%). 
 (b) No
Multiple Royalties. If the manufacture, use or sale of any Licensed Product is covered by more than one of the Patent Rights, multiple royalties shall not be due. 

4.2 Sublicense Revenue. In addition to the running royalties in Section 4.1, SIENNA shall pay NANOCOMPOSIX [***] percent
([***]%) of Sublicense Revenue resulting from each sublicense agreement (including any extensions, amendments and restatements thereof), [***]. Such amounts shall be payable for each Reporting Period and shall be due to NANOCOMPOSIX
within [***] ([***]) days of the end of each Reporting Period. 
 4.3 Payments. 

(a) Method of Payment. All payments under this Agreement should be made payable to NANOCOMPOSIX and sent to the address identified in
Section 15.1. 
 (b) Payments in U.S. Dollars. All payments due under this Agreement shall be payable in United States dollars.
Conversion of foreign currency to U.S. dollars shall be made at the conversion rate existing in the United States (as reported in the Wall Street Journal) on the last working day of the calendar quarter of the applicable
Reporting Period. Such payments shall be [***], subject to the following [***]. 
 (c) Withholding Taxes. If any
amounts are required under US or other laws to be withheld from payments otherwise due to NANOCOMPOSIX, SIENNA shall so notify NANOCOMPOSIX, obtain appropriate documentation of such requirement, deduct from payments to NANOCOMPOSIX the appropriate
amount of withholding taxes imposed hereunder, and pay such taxes on behalf of NANOCOMPOSIX. SIENNA shall provide NANOCOMPOSIX with receipts or certificates showing the payment of the amounts withheld pursuant to this Section. SIENNA shall use
[***] to provide all forms, documents, and/or other information necessary to comply with or reduce any taxes payable pursuant to this Section or necessary to establish NANOCOMPOSIX’s right to a tax credit in respect of any such taxes.
Any other taxes (other than any based on NANOCOMPOSIX’s income) levied by any authorities in the Territory [***]. 
 (d) Late
Payments. Any payments to NANOCOMPOSIX that are not paid on or before the date such payments are due under this Agreement shall bear interest, to the extent permitted by law, at [***] ([***]) percentage points above the Prime Rate
of interest as reported in the Wall Street Journal on the date payment is due. 
 ARTICLE 5 

REPORTS AND RECORDS 
 5.1
Frequency of Reports. 
 (a) Before First Commercial Sale. Prior to the First Commercial Sale in any country, SIENNA shall
deliver reports to NANOCOMPOSIX annually, within [***] ([***]) days after the end of each calendar year, containing information concerning the immediately preceding calendar year, as further described in Section 5.2. 

  
 Confidential Portions
of this Exhibit marked as [***] have been omitted pursuant to a request for 
 confidential treatment and have been filed separately with the
Securities and Exchange Commission. 

  
 8 

 Confidential Treatment Requested by Sienna Biopharmaceuticals, Inc. 

 

 (b) Upon First Commercial Sale. SIENNA shall report to NANOCOMPOSIX the date of First
Commercial Sale in any country within [***] ([***]) days of occurrence in each country. 
 (c) After First Commercial
Sale. After the First Commercial Sale in any country, SIENNA shall deliver reports to NANOCOMPOSIX within [***] ([***]) days of the end of each Reporting Period, containing information concerning the immediately preceding Reporting
Period, as further described in Section 5.2. 
 5.2 Content of Reports and Payments. Each report delivered by SIENNA to
NANOCOMPOSIX shall contain at least the following information for the immediately preceding Reporting Period: 
 (a) the number of Licensed
Products sold by SIENNA, its Affiliates and Sublicensees to independent third parties in each country, and the name of each Licensed Product; 

(b) the gross price charged by SIENNA, its Affiliates and Sublicensees for each Licensed Product in each country; 

(c) calculation of Net Sales for the applicable Reporting Period in each country, including, without limitation, a listing of applicable
deductions; 
 (d) total royalty payable on Net Sales in U.S. dollars, together with the exchange rates used for conversion; and 

(e) the percentage of Sublicense Revenue due pursuant to Section 4.2. 

For clarity, with respect to Sublicensees, the reports shall include the information reported by Sublicensees to SIENNA during the applicable
Reporting Period. If no amounts are due to NANOCOMPOSIX for any Reporting Period, the report shall so state. 
 5.3 Records. SIENNA
shall maintain, and shall cause its Affiliates and Sublicensees to maintain, complete and accurate records relating to amounts payable to NANOCOMPOSIX in relation to this Agreement. The relevant entity shall retain such records for at least
[***] ([***]) years following the end of the calendar year to which they pertain, during which time a certified, independent public accountant selected by NANOCOMPOSIX and reasonably acceptable to SIENNA shall have the right, at
NANOCOMPOSIX’S expense, to inspect such records during normal business hours to verify any reports and payments made or compliance in other respects under this Agreement. In the event that any audit performed under this Section 5.3 reveals
an underpayment in excess of [***] percent ([***]%), SIENNA shall bear the [***] cost of such audit and shall remit any amounts due to NANOCOMPOSIX within [***] ([***]) days of receiving notice thereof from
NANOCOMPOSIX. The reports and records provided by SIENNA hereunder shall be regarded as SIENNA’s Confidential Information and NANOCOMPOSIX hereby covenants that it shall not use or disclose any information included in such reports for any
purpose other than determining whether SIENNA, its Affiliates and Sublicensees have complied with their obligations under this Agreement. The terms of this Agreement constitute both Parties’ Confidential Information. 

  
 Confidential Portions
of this Exhibit marked as [***] have been omitted pursuant to a request for 
 confidential treatment and have been filed separately with the
Securities and Exchange Commission. 

  
 9 

 Confidential Treatment Requested by Sienna Biopharmaceuticals, Inc. 

 

 ARTICLE 6 

CONFIDENTIALITY 
 6.1
Nondisclosure and Non-Use. During the Term and for [***] ([***]) years thereafter, a Party receiving Confidential Information of the other Party (or that has received any such Confidential
Information from the other Party prior to the Effective Date) shall (a) maintain in confidence such Confidential Information using not less than the efforts such Party uses to maintain in confidence its own proprietary industrial information of
similar kind and value, (b) not disclose such Confidential Information to any Third Party without the prior written consent of the other Party, except for disclosures expressly permitted below, and (c) not use such Confidential Information
for any purpose except those permitted by this Agreement. The Materials and all information and documentation regarding the Materials constitutes NANOCOMPOSIX’S Confidential Information to the extent not disclosed or described in the Patent
Rights. 
 6.2 Exceptions. The obligations in Section 6.1 shall not apply with respect to any portion of the Confidential
Information that the receiving Party can show by competent proof: (a) is publicly disclosed by the disclosing Party, either before or after it is disclosed to the receiving Party hereunder; or (b) was known to the receiving Party or any of
its Affiliates, without any obligation to keep it confidential or any restriction on its use, prior to disclosure by the disclosing Party; (c) is subsequently disclosed to the receiving Party or any of its Affiliates by a Third Party lawfully
in possession thereof and is disclosed without any obligation to keep it confidential or any restriction on its use; (d) is published by a disclosing Party or a Third Party or otherwise becomes publicly available or enters the public domain,
either before or after it is disclosed to the receiving Party; or (e) has been independently developed by employees or contractors of the receiving Party or any of its Affiliates without the aid, application or use of Confidential Information
of the disclosing Party. 
 6.3 Authorized Disclosure. The obligations in Section 6.1 shall not apply with respect to any
portion of the Confidential Information that the receiving Party can show by competent proof: 
 (a) The receiving Party may disclose
Confidential Information belonging to the other Party to the extent (and only to the extent) such disclosure is reasonably necessary in the following instances: 

(i) filing or prosecuting patents as set forth in this Agreement; 

(ii) Company’s research, development or Commercialization (including any import, manufacture, use, offer for sale, or sale) activities,
including Company’s regulatory filings, with respect to Licensed Products, including any regulatory approvals or applications therefor; 

(iii) prosecuting or defending litigation in relation to the Patent Rights or this Agreement, including responding to a subpoena in a Third
Party litigation; provided it has used [***] to obtain a protective order for such Confidential Information; 
 (iv) subject to
Section 6.4, complying with applicable laws (including the rules and regulations of the Securities and Exchange Commission or any national securities exchange) and with judicial process, if in the reasonable opinion of the receiving
Party’s counsel, such disclosure is necessary for such compliance; provided, however, that [***], the receiving Party shall give the disclosing Party reasonable advance notice of such disclosure requirement (which shall include a copy of
any applicable subpoena or order) and shall afford the disclosing Party a reasonable opportunity to oppose, limit or secure confidential treatment for such required disclosure, and in the event of any such required disclosure, the receiving Party
shall disclose only that portion of the Confidential Information of the disclosing Party that the receiving Party is legally required to disclose; 

  
 Confidential Portions
of this Exhibit marked as [***] have been omitted pursuant to a request for 
 confidential treatment and have been filed separately with the
Securities and Exchange Commission. 

  
 10 

 Confidential Treatment Requested by Sienna Biopharmaceuticals, Inc. 

 

 (v) disclosure, in connection with the performance of this Agreement and solely on a
“need to know basis”, to Affiliates, existing or potential collaborators (including existing or potential co-marketing and co-promotion contractors), research
collaborators, employees, consultants, or agents, each of whom prior to disclosure must be bound by written obligations of confidentiality and non-use no less restrictive than the obligations set forth in this
Article 6; provided however that the receiving Party shall remain responsible for any failure by any Person who receives Confidential Information pursuant to this Article 6 to treat such Confidential Information as required under this Article 6; and

 (vi) made by such Party to existing or potential acquirers or merger candidates; investment bankers; public and private sources of
funding; existing or potential investors, venture capital firms or other financial institutions or investors for purposes of obtaining financing, provided that such Party has used [***] to secure an agreement from any such Third Party to be
bound by obligations of confidentiality and restrictions on use of Confidential Information that are no less restrictive than the obligations in this Agreement; and 

(b) If and whenever any Confidential Information is disclosed in accordance with this Section 6.3, such disclosure shall not cause any
such information to cease to be Confidential Information except to the extent that such disclosure results in a public disclosure of such information (otherwise than by breach of this Agreement). Where [***] and subject to Section 6.4,
the receiving Party shall notify the disclosing Party of the receiving Party’s intent to make such disclosure pursuant to this Section 6.3 sufficiently prior to making such disclosure so as to allow the disclosing Party adequate time to
take whatever action it may deem appropriate to protect the confidentiality of the information. 
 6.4 Terms of this Agreement. The
Parties acknowledge that the terms of this Agreement shall be treated as Confidential Information of both Parties. For the avoidance of doubt, this Section 6.4 shall in no way prevent a Party from disclosing the existence of this Agreement or
any terms of this Agreement in order to seek legal advice whenever deemed appropriate by such Party or to enforce such Party’s rights under this Agreement, whether through arbitral proceedings, court proceedings or otherwise, or to defend
itself against allegations or claims relating to this Agreement, or to comply with applicable law (except as provided in Section 6.5) when advised in a written opinion of outside counsel that terms of the Agreement are required to be disclosed
to comply with applicable law. 
 6.5 Securities Filings. Notwithstanding anything to the contrary in this Agreement, in the event
either Party proposes to file with the Securities and Exchange Commission or the securities regulators of any state or other jurisdiction a registration statement or any other disclosure document which describes or refers to this Agreement under the
Securities Act of 1933, as amended, the Securities Exchange Act, of 1934, as amended, any other applicable securities law or the rules of any national securities exchange, the Party shall notify the other Party of such intention and shall use
[***] to provide such other Party with a copy of relevant portions of the proposed filing not less than [***] ([***]) business days prior to (but in no event later than [***] ([***]) business days prior to) such
filing (and any revisions to such portions of the proposed filing a reasonable time prior to the filing thereof), including any exhibits thereto relating to this Agreement, and shall use [***] to obtain confidential treatment of any
information concerning this Agreement that such other Party requests be kept confidential, and shall only disclose Confidential Information which it is advised by counsel is legally required to be disclosed. No such notice shall be required under
this Section 6.5 if the substance of the description of or reference to this Agreement contained in the proposed filing has been included in any previous filing made by the either Party hereunder or otherwise approved by the other Party. 

  
 Confidential Portions
of this Exhibit marked as [***] have been omitted pursuant to a request for 
 confidential treatment and have been filed separately with the
Securities and Exchange Commission. 

  
 11 

 Confidential Treatment Requested by Sienna Biopharmaceuticals, Inc. 

 

 6.6 Publications. SIENNA may publish or present data and/or results relating to a
Licensed Product in scientific journals and/or at scientific conferences, provided that SIENNA shall notify NANOCOMPOSIX at least [***] ([***]) days in advance of the intended submission for publication or presentation of any proposed
abstract, manuscript or presentation which discloses Confidential Information of NANOCOMPOSIX or discloses a patentable invention by delivering a copy thereof to NANOCOMPOSIX. NANOCOMPOSIX shall have [***] ([***]) business days from
its receipt of any such abstract, manuscript or presentation in which to notify SIENNA in writing of any specific, reasonable objections to the disclosure, based on concern regarding the specific disclosure of Confidential Information of
NANOCOMPOSIX, and SIENNA will delete any NANOCOMPOSIX Confidential Information, and consider any other such objections in good faith, including whether it is necessary or advisable to delete any other information from such proposed publication. Once
any such abstract or manuscript is accepted for publication, SIENNA shall provide NANOCOMPOSIX with a copy of the final version of the manuscript or abstract. 

ARTICLE 7 
 PATENT
PROSECUTION 
 7.1 Responsibility for Patent Rights. As of the Effective Date, on the going-forward basis SIENNA (a) shall
be solely responsible for preparation, filing, prosecution, and maintenance of the Patent Rights and for payment of patent expenses (including attorney expenses) with respect to the Patent Rights relating to the forgoing; (b) may select
attorneys and prosecute and maintain the Patent Rights as it sees fit; (c) must consult with NANOCOMPOSIX and have due regard to NANOCOMPOSIX’s wishes prior to making decisions regarding the prosecution and maintenance of Patent Rights;
(d) must provide copies of proposed correspondence with patent offices or amendments to any claim of the Patent Rights to NANOCOMPOSIX at least [***] days in advance; (e) must [***] to [***] (except that
[***] where the [***] is [***] for a [***] to be [***]); and (f) must [***] where [***] has [***] to [***], and [***]. If SIENNA (i) intends not to file any available
application for Patent Rights in a country, (ii) wishes to allow any such application or granted Patent Right to be abandoned or lapse, or (iii) chooses not to file an application or otherwise seek protection for an embodiment of the
Patent Rights requested by NANOCOMPOSIX (each of the foregoing (i)-(iii), an “Unelected Right”), having first complied with clause (f) above, SIENNA must give NANOCOMPOSIX notice at least [***] days prior to any
deadline by which action must to take to file such application or avoid such abandonment or lapse, and NANOCOMPOSIX may, [***], elect to take over the filing, prosecution, and/or maintenance of such Unelected Right by giving written notice to
SIENNA, in which case such Unelected Right will immediately cease to form part of the Patent Rights. 
 ARTICLE 8 

INFRINGEMENT 
 8.1
Notification of Infringement. Each Party shall provide written notice to the other Party promptly after becoming aware of any infringement of the Patent Rights by a third party (including any third party impermissibly using the Materials in
the Field) and of any available evidence thereof, provided that [***] shall [***] to [***] of [***]. 

  
 Confidential Portions
of this Exhibit marked as [***] have been omitted pursuant to a request for 
 confidential treatment and have been filed separately with the
Securities and Exchange Commission. 

  
 12 

 Confidential Treatment Requested by Sienna Biopharmaceuticals, Inc. 

 

 8.2 Right to Prosecute Infringements and Defend the Patent Rights. 

(a) SIENNA shall have the first right (but not the obligation), [***], to bring suit (or take other appropriate legal action) against
any actual, alleged or threatened infringement of the Patent Rights in the Field, and to defend any of the Patent Rights in any legal or administrative proceeding. The total cost of any such infringement action [***] shall be [***].

 (b) If SIENNA does not file any action or proceeding against any infringement in the Field within [***] ([***]) months
after the later of (i) either Party’s notice to the other under Section 8.1, or (ii) a written request from NANOCOMPOSIX to take action with respect to such infringement, then NANOCOMPOSIX (or a third party authorized by
NANOCOMPOSIX) shall have the right (but not the obligation), [***], to bring suit (or take other appropriate legal action) against such actual, alleged or threatened infringement, [***]. If SIENNA does not promptly assume the defense
of any of the Patent Rights in any legal or administrative proceeding, then NANOCOMPOSIX [***] shall have the right (but not the obligation), [***], to defend the Patent Rights against such legal or administrative proceeding. 

8.3 Recovery. In the event that either Party [***]) exercises the rights conferred in this Article 8 and recovers from any
third party any damages or other sums in such action, such damages or other sums recovered shall first be applied to all out-of-pocket costs and expenses incurred by the
Parties [***]) in connection therewith (including, without limitation, attorneys fees). If such recovery is insufficient to cover all such costs and expenses of both Parties (or, if applicable, the costs and expenses of a third party
[***]), the controlling Party’s costs (or, if applicable, the costs of any third party [***] shall be paid in full first before any of the other Party’s costs. If after such reimbursement any funds shall remain from such
damages or other sums recovered, such funds shall be retained by the Party that controlled the action or proceeding under this Article 8; provided, however, that (a) if SIENNA is the Party that controlled such action or proceeding,
NANOCOMPOSIX shall receive out of any such remaining recovery received by SIENNA [***] and (b) if NANOCOMPOSIX [***] is the entity that controlled such action or proceeding, the remaining recovery received by NANOCOMPOSIX
[***] shall be split at a rate of [***] percent ([***]%) for NANOCOMPOSIX and [***] percent ([***]%) for SIENNA. 

8.4 Cooperation. Each Party agrees to cooperate in any action under this Article 8 which is controlled by the other Party,
including, without limitation, joining such action as a party plaintiff if necessary or desirable for initiation or continuation of such action; provided that the controlling Party reimburses the cooperating Party promptly for any reasonable costs
and expenses incurred by the cooperating Party in connection with providing such assistance; and further provided that neither Party shall be required to transfer any right, title or interest in or to any property to the other Party or any third
party to confer standing on a Party hereunder. 
 8.5 Certain Limitations. SIENNA shall not (or permit any of its Affiliates or
Sublicensees to) take any position with respect to, or compromise or settle, any action involving the enforcement of any Patent Rights in any way that would be [***] to directly and adversely affect their scope, validity or enforceability
without the prior written consent of NANOCOMPOSIX, which consent shall not be unreasonably withheld, conditioned or delayed. NANOCOMPOSIX shall not take any position with respect to, or compromise or settle, any action involving the enforcement of
any Patent Rights within the Field in any way that would be [***] to directly and adversely affect their scope, validity or enforceability without the prior written consent of SIENNA, which consent shall not be unreasonably withheld,
conditioned or delayed. 

  
 Confidential Portions
of this Exhibit marked as [***] have been omitted pursuant to a request for 
 confidential treatment and have been filed separately with the
Securities and Exchange Commission. 

  
 13 

 Confidential Treatment Requested by Sienna Biopharmaceuticals, Inc. 

 

 ARTICLE 9 

INDEMNIFICATION AND INSURANCE 

9.1 Indemnification. SIENNA hereby agrees to indemnify, defend (by counsel reasonably acceptable to NANOCOMPOSIX) and hold harmless
NANOCOMPOSIX and any parent, subsidiary or other affiliated entity and their trustees, directors, officers, employees, scientists, agents, successors, assigns and other representatives (collectively, the “Indemnitees”) from and
against all damages, liabilities, losses and other expenses, including, without limitation, reasonable attorney’s fees, expert witness fees and costs, regarding any claims, suits or proceedings brought by a third party, whether or not a lawsuit
or other proceeding is filed (collectively “Claim”), that arise out of or relate to (a) any product, process, or service that is made, used, sold, imported, or performed pursuant to any right or license granted under this
Agreement (including without limitation product liability and infringement claims), (b) SIENNA’s or its Affiliate’s or Sublicensee’s failure to comply with any applicable laws, rules or regulations in connection with this
Agreement, and (c) the negligent or willful acts or omissions of SIENNA, its Affiliate or Sublicensee; except, in each of (a), (b), and (c), to the extent arising out of or relating to any breach of this Agreement by NANOCOMPOSIX and/or the
negligent or willful acts or omissions of NANOCOMPOSIX and/or any Indemnitees. [***]. Notwithstanding the above, Indemnitees, at their expense, shall have the right to retain separate independent counsel to assist in defending any such
Claims. In the event SIENNA fails to promptly indemnify and defend such Claims or pay Indemnitees’ expenses as provided above, Indemnitees shall have the right to defend themselves, and in that case, SIENNA shall reimburse Indemnitees for all
of their reasonable attorney’s fees, costs and damages incurred in settling or defending such Claims within [***] ([***]) days of each of Indemnitees’ written requests. [***]. 

9.2 Insurance. SIENNA shall obtain and carry in full force and effect commercial general liability insurance, including, without
limitation, product liability and errors and omissions insurance which shall protect SIENNA and Indemnitees with respect to events covered by Section 9.1, and which shall protect SIENNA and Indemnitees with respect to any product, process, or
service that is made, used, sold, imported, or performed pursuant to any right or license granted under this Agreement. Commencing on the date of the First Commercial Sale, the limits of such insurance shall not be less than [***] Dollars
($[***]) per occurrence with an aggregate of [***] Dollars ($[***]) for bodily injury including death; and [***] Dollars ($[***]) per occurrence with an aggregate of [***] Dollars ($[***]) for
property damage. In the alternative, SIENNA may self-insure subject to prior approval of NANOCOMPOSIX. SIENNA shall provide NANOCOMPOSIX with Certificates of Insurance evidencing compliance with this Section 9.2. SIENNA shall continue to
maintain such insurance or self-insurance after the expiration or termination of this Agreement during any period in which SIENNA or any Affiliate or Sublicensee continues to make, use, sell or import a product that was a Licensed Product under this
Agreement and thereafter for a period of [***] ([***]) years. 
 ARTICLE 10 

REPRESENTATIONS OR WARRANTIES 

10.1 By NANOCOMPOSIX. NANOCOMPOSIX represents and warrants that: (a) it solely and exclusively owns the patents and applications
included within the Patent Rights; (b) it has the power and authority to grant the licenses provided for herein to SIENNA, and that it has not earlier granted, or assumed any obligation to grant, any rights in the Patent Rights to any third
party that would conflict with the rights granted to SIENNA herein; (c) this Agreement constitutes the legal, valid and binding obligation of NANOCOMPOSIX, enforceable against such NANOCOMPOSIX in accordance with its terms; and (d) as of
the Effective Date and the Restatement Date and to NANOCOMPOSIX’S actual knowledge, there is no infringement of the Patent Rights by any third party product or process. 

  
 Confidential Portions
of this Exhibit marked as [***] have been omitted pursuant to a request for 
 confidential treatment and have been filed separately with the
Securities and Exchange Commission. 

  
 14 

 Confidential Treatment Requested by Sienna Biopharmaceuticals, Inc. 

 

 10.2 By SIENNA. SIENNA represents and warrants to NANOCOMPOSIX that: (i) the
execution and delivery of this Agreement and the performance of the transactions contemplated hereby have been duly authorized by all appropriate SIENNA corporate action; and (ii) this Agreement is a legal and valid obligation binding upon
SIENNA and enforceable in accordance with its terms, and (iii) the execution, delivery and performance of this Agreement by the Parties does not conflict with any agreement, instrument or understanding to which SIENNA is a party or by which it
is bound. 
 10.3 Disclaimer of Warranties. EXCEPT AS OTHERWISE BE EXPRESSLY SET FORTH IN THIS AGREEMENT, NANOCOMPOSIX MAKES NO OTHER
WARRANTIES CONCERNING THE PATENT RIGHTS OR MATERIALS OR ANY OTHER MATTER WHATSOEVER, INCLUDING, WITHOUT LIMITATION, ANY EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE,
NON-INFRINGEMENT OF THIRD PARTY RIGHTS OR ARISING OUT OF COURSE OF CONDUCT OR TRADE CUSTOM OR USAGE, AND NANOCOMPOSIX DISCLAIMS ALL SUCH EXPRESS OR IMPLIED WARRANTIES. [***]. NANOCOMPOSIX MAKES NO
WARRANTY OR REPRESENTATION AS TO THE [***], OR THAT [***]. FURTHER, NANOCOMPOSIX HAS MADE NO INVESTIGATION AND MAKES NO REPRESENTATION THAT [***]. 

10.4 Limitation of Liability. EXCEPT FOR SIENNA’S INDEMNITY OBLIGATIONS UNDER SECTION 9.1 OR CLAIMS ARISING UNDER Article 6,
IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR ANY INDIRECT, SPECIAL, INCIDENTAL, EXEMPLARY OR CONSEQUENTIAL DAMAGES (INCLUDING, WITHOUT LIMITATION, DAMAGES FOR LOSS OF PROFITS OR EXPECTED SAVINGS OR OTHER ECONOMIC LOSSES) ARISING OUT OF OR IN
CONNECTION WITH THIS AGREEMENT OR ITS SUBJECT MATTER. NANOCOMPOSIX’S AGGREGATE LIABILITY, IF ANY, FOR ALL DAMAGES OF ANY KIND RELATING TO THIS AGREEMENT OR ITS SUBJECT MATTER SHALL NOT EXCEED [***]. THE FOREGOING EXCLUSIONS AND
LIMITATIONS SHALL APPLY TO ALL CLAIMS AND ACTIONS OF ANY KIND AND ON ANY THEORY OF LIABILITY, WHETHER BASED ON CONTRACT, TORT (INCLUDING, WITHOUT LIMITATION, NEGLIGENCE OR STRICT LIABILITY), OR ANY OTHER GROUNDS, AND REGARDLESS OF WHETHER THE PARTY
HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, AND NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY. THE PARTIES FURTHER AGREE THAT EACH WARRANTY DISCLAIMER, EXCLUSION OF DAMAGES OR OTHER LIMITATION OF LIABILITY HEREIN IS
INTENDED TO BE SEVERABLE AND INDEPENDENT OF THE OTHER PROVISIONS SINCE THEY EACH REPRESENT SEPARATE ELEMENTS OF RISK ALLOCATION BETWEEN THE PARTIES. 

ARTICLE 11 

ASSIGNMENT 
 Either Party
may assign all of its rights and obligations under this Agreement to a successor of such Party or such party’s business or assets in connection with the merger, consolidation, reorganization or sale of all or substantially all of its assets or
that portion of its business to which this Agreement relates (in one or more related transactions) provided that the assignee agrees in writing to be bound by all of the terms and conditions of this Agreement. 

  
 Confidential Portions
of this Exhibit marked as [***] have been omitted pursuant to a request for 
 confidential treatment and have been filed separately with the
Securities and Exchange Commission. 

  
 15 

 Confidential Treatment Requested by Sienna Biopharmaceuticals, Inc. 

 

 ARTICLE 12 

GENERAL COMPLIANCE WITH LAW 

12.1 Compliance with Laws. SIENNA and its Affiliates and Sublicensees shall comply with all applicable local, state, federal, and
international laws and regulations relating to the development, manufacture, use, sale and import of Licensed Products. 
 12.2 Export
Control. SIENNA and its Affiliates and Sublicensees shall comply with all United States laws and regulations controlling the export of certain commodities and technical data, including, without limitation, all Export Administration Regulations
of the United States Department of Commerce. Among other things, these laws and regulations prohibit or require a license for the export of certain types of commodities and technical data to specified countries. SIENNA hereby gives written assurance
that it shall comply with, and shall cause its Affiliates and Sublicensees to comply with, all United States export control laws and regulations, that it bears sole responsibility for any violation of such laws and regulations by itself or its
Affiliates or Sublicensees, and that it shall indemnify, defend, and hold the Indemnitees harmless (in accordance with Section 9.1) for the consequences of any such violation. 

ARTICLE 13 

TERMINATION 
 13.1
Voluntary Termination by SIENNA. SIENNA shall have the right to terminate this Agreement, for any reason, upon at least three (3) months prior written notice to NANOCOMPOSIX, such notice to state the date at least three (3) months
in the future upon which termination is to be effective. 
 13.2 Termination for Cause. 

(a) Nonpayment. In the event SIENNA fails to pay any undisputed amounts due and payable to NANOCOMPOSIX hereunder, and fails to make
such payments within thirty (30) days after receiving written notice of such failure, NANOCOMPOSIX may terminate this Agreement immediately upon written notice to SIENNA. 

(b) Material Breach. In the event SIENNA commits a material breach of its obligations under this Agreement and fails to cure that
breach within thirty (30) days after receiving written notice thereof, NANOCOMPOSIX may terminate this Agreement immediately upon written notice to SIENNA. 

(c) Notwithstanding Section 13.2(a) and (b), if SIENNA disputes in good faith the existence or materiality of such breach and provides notice
to NANOCOMPOSIX of such dispute within such cure period, NANOCOMPOSIX will not have the right to terminate this Agreement in accordance with Section 13.2(a) or (b), as applicable, unless and until it has been determined in accordance with Article 14
that this Agreement was materially breached by SIENNA and SIENNA failed to cure such breach within the applicable cure period. It is understood and acknowledged that during the pendency of such a dispute, all of the terms and conditions of this
Agreement will remain in effect and the Parties will continue to perform all of their respective obligations hereunder. The Parties further agree that any payments that are made by SIENNA to NANOCOMPOSIX pursuant to this Agreement pending resolution
of the dispute will be promptly refunded if a court or arbitrator determines pursuant to Article 14 that such payments are to be refunded by NANOCOMPOSIX to SIENNA. 

  
 Confidential Portions
of this Exhibit marked as [***] have been omitted pursuant to a request for 
 confidential treatment and have been filed separately with the
Securities and Exchange Commission. 

  
 16 

 Confidential Treatment Requested by Sienna Biopharmaceuticals, Inc. 

 

 (d) Milestones. If SIENNA does not receive FDA regulatory approval to sell a Licensed
Product within seven (7) years of the Prior Restatement Date, then NANOCOMPOSIX may terminate this Agreement upon notice to SIENNA. 

(e) Insolvency/Bankruptcy. If either Party files for protection under bankruptcy laws, makes an assignment for the benefit of
creditors, appoints or suffers appointment of a receiver or trustee over its property, files a petition under any bankruptcy or insolvency act or has any such petition filed against it which is not discharged within sixty (60) days of the
filing thereof, then the other Party may terminate this Agreement effective immediately upon written notice to such Party. 
 13.3 Effect
of Expiration or Termination. 
 (a) Licensed Rights. Subject to Section 13.3(c) hereof, Expiration or termination of this
Agreement shall immediately and automatically terminate all licenses granted by NANOCOMPOSIX to SIENNA hereunder, and all sublicenses granted by SIENNA (subject to the provisions of Section 3.2). 

(b) Surviving Provisions. Expiration or termination of this Agreement for any reason shall not relieve either Party of any liability or
obligation which accrued hereunder prior to the effective date of such termination or expiration. The following provisions shall survive the expiration or termination of this Agreement: SIENNA’s payment obligations, Article 1,
Article 9, Article 10, Article 11, Article 12, Article 14 and Article 15, and Sections 3.4, 5.2 (but only with respect to obligation to provide final report and payment), 5.3 and 13.3. 

(c) Inventory. Upon the termination of this Agreement, SIENNA and its Affiliates and Sublicensees may complete and sell any work-in-progress and inventory of Licensed Products that exist as of the effective date of termination, provided that (i) SIENNA pays NANOCOMPOSIX the applicable running
royalty or other amounts due on such sales of Licensed Products in accordance with the terms and conditions of this Agreement, and (ii) SIENNA and its Affiliates and Sublicensees shall complete and sell all work-in-progress and inventory of Licensed Products within [***] ([***]) months after the effective date of termination. 

(d) Cumulative Remedy. The termination provisions of this Section are in addition to any other relief and remedies available to either
Party under this Agreement and at law. 
 ARTICLE 14 

DISPUTE RESOLUTION 
 14.1
Mandatory Procedures. The Parties agree that any dispute arising out of or relating to this Agreement shall be resolved solely by means of the procedures set forth in this Article 14, and that such procedures constitute legally binding
obligations that are an essential provision of this Agreement. If either Party fails to observe the procedures of this Article 14, as may be modified by their written agreement, the other Party may bring an action for specific performance of
these procedures in any court of competent jurisdiction. 
 14.2 Equitable Remedies. Although the procedures specified in this
Article 14 are the sole and exclusive procedures for the resolution of disputes arising out of or relating to this Agreement, either Party may seek a preliminary injunction or other provisional equitable relief if, in its reasonable judgment,
such action is necessary to avoid irreparable harm to itself or to preserve its rights under this Agreement, including without limitation with respect to claims under Article 6 and Article 9. 

  
 Confidential Portions
of this Exhibit marked as [***] have been omitted pursuant to a request for 
 confidential treatment and have been filed separately with the
Securities and Exchange Commission. 

  
 17 

 Confidential Treatment Requested by Sienna Biopharmaceuticals, Inc. 

 

 14.3 Dispute Resolution Procedures. Except as otherwise stated herein, any controversy
or claim arising out of or relating to this Agreement, or the breach thereof, shall be settled by binding confidential arbitration in accordance with the [***], and the procedures set forth below. In the event of any inconsistency between the
Rules of AAA and the procedures set forth below, the procedures set forth below shall control. Judgment upon the award rendered by the arbitrators may be enforced in any court having jurisdiction thereof. 

(a) The location of the arbitration shall be in the County of Los Angeles, CA. NANOCOMPOSIX and SIENNA hereby irrevocably submit to the
exclusive jurisdiction and venue of the AAA arbitration panel selected by the Parties and located in Los Angeles, CA for any dispute regarding this Agreement, and to the exclusive jurisdiction and venue of the federal and state courts located in Los
Angeles, CA for any action or proceeding to enforce an arbitration award or as otherwise provided in Section 14.3(e), and waive any right to contest or otherwise object to such jurisdiction or venue. 

(b) The arbitration shall be conducted by a panel of three neutral arbitrators who are independent and disinterested with respect to the
Parties, this Agreement, and the outcome of the arbitration. Each Party shall appoint one neutral arbitrator, and these two arbitrators so selected by the Parties shall then select the third arbitrator, and all arbitrators must have at least
[***] ([***]) years experience in mediating or arbitrating cases regarding the same or substantially similar subject matter as the dispute between NANOCOMPOSIX and SIENNA. If one Party has given written notice to the other Party as to
the identity of the arbitrator appointed by the Party, and the Party thereafter makes a written demand on the other Party to appoint its designated arbitrator within the next [***] days, and the other Party fails to appoint its designated
arbitrator within [***] days after receiving said written demand, then the arbitrator who has already been designated shall appoint the other two arbitrators. 

(c) The arbitrators shall decide any disputes and shall control the process concerning these
pre-hearing discovery matters. Pursuant to the Rules of AAA, the Parties may subpoena witnesses and documents for presentation at the hearing. 

(d) Prompt resolution of any dispute is important to both Parties; and the Parties agree that the arbitration of any dispute shall be
conducted expeditiously. The arbitrators are instructed and directed to assume case management initiative and control over the arbitration process (including, without limitation, scheduling of events,
pre-hearing discovery and activities, and the conduct of the hearing), in order to complete the arbitration as expeditiously as is reasonably practical for obtaining a just resolution of the dispute. 

(e) The arbitrators may grant any legal or equitable remedy or relief that the arbitrators deem just and equitable, to the same extent that
remedies or relief could be granted by a state or federal court, provided however, that no punitive damages may be awarded. No court action shall be maintained seeking punitive damages. The decision of any two of the three arbitrators appointed
shall be binding upon the Parties. Notwithstanding anything to the contrary in this Agreement, prior to or while an arbitration proceeding is pending, either Party has the right to seek and obtain injunctive and other equitable relief from a court
of competent jurisdiction to enforce that Party’s rights hereunder. 
 (f) The expenses of the arbitration, including, without
limitation, the arbitrators’ fees, expert witness fees, and attorney’s fees, may be awarded to the prevailing Party, in the discretion of the arbitrators, or may be apportioned between the Parties in any manner deemed appropriate by the
arbitrators. Unless and until the arbitrators decide that one Party is to pay for all (or a share) of such expenses, both Parties shall [***] of the arbitrators’ fees as and when billed by the arbitrators. 

  
 Confidential Portions
of this Exhibit marked as [***] have been omitted pursuant to a request for 
 confidential treatment and have been filed separately with the
Securities and Exchange Commission. 

  
 18 

 Confidential Treatment Requested by Sienna Biopharmaceuticals, Inc. 

 

 (g) Notwithstanding the foregoing, any disputes arising hereunder with respect to the
inventorship, validity, enforceability or other aspect of intellectual property rights shall be resolved by a court of competent jurisdiction and not by arbitration. 

(h) Except as set forth below and as necessary to obtain or enforce a judgment upon any arbitration award, the Parties shall keep confidential
the fact of the arbitration, the dispute being arbitrated, and the decision of the arbitrators. Notwithstanding the foregoing, the Parties may disclose information about the arbitration to persons who have a need to know, such as directors,
trustees, management employees, witnesses, experts, investors, attorneys, lenders, insurers, actual or potential collaborators or corporate partners of SIENNA, actual or potential acquirors of SIENNA, and others who may be directly affected provided
that such persons are bound to keep such information confidential. Additionally, if a Party has stock which is publicly traded, the Party may make such disclosures as are required by applicable securities laws, but shall use commercially reasonably
efforts to seek confidential treatment for such disclosure. 
 14.4 Statute of Limitations. The Parties agree that all applicable
statutes of limitation and time-based defenses (such as estoppel and laches) shall be tolled while the procedures set forth in this Article are pending. The Parties shall cooperate in taking any actions necessary to achieve this result. 

ARTICLE 15 

MISCELLANEOUS 
 15.1
Notice. Any notices required or permitted under this Agreement shall be in writing, shall specifically refer to this Agreement, and shall be sent by hand, recognized national overnight courier, confirmed facsimile transmission, or registered
or certified mail, postage prepaid, return receipt requested, to the following addresses or facsimile numbers of the Parties: 
  

			
	If to NANOCOMPOSIX:	  	4878 Ronson Court, Suite K
		  	San Diego, CA 92111
		  	Attention: Steven Oldenburg
		  	Email: [***]
		
	If to SIENNA:	  	30699 Russell Ranch Road, Suite 140
		  	Westlake Village, CA 91362
		  	Attention: General Counsel
		  	Email: [***]

 All notices under this Agreement shall be deemed effective upon receipt. A Party may change its contact
information immediately upon written notice to the other Party in the manner provided in this Section 15.1. 
 15.2 Governing
Law. This Agreement and all disputes arising out of or related to this Agreement, or the performance, enforcement, breach or termination hereof, and any remedies relating thereto, shall be construed, governed, interpreted and applied in
accordance with the laws of the State of California, without regard to conflict of laws principles, except that questions affecting the construction and effect of any patent shall be determined by the law of the country in which the patent shall
have been granted. 
 15.3 Force Majeure. Neither Party shall be responsible for delays resulting from causes beyond the reasonable
control of such Party, including, without limitation fire, explosion, flood, war, 

  
 Confidential Portions
of this Exhibit marked as [***] have been omitted pursuant to a request for 
 confidential treatment and have been filed separately with the
Securities and Exchange Commission. 

  
 19 

 Confidential Treatment Requested by Sienna Biopharmaceuticals, Inc. 

 

 
strike, or riot, provided that the nonperforming Party uses commercially reasonable efforts to avoid or remove such causes of nonperformance and continues performance under this Agreement with
reasonable dispatch whenever such causes are removed. 
 15.4 Amendment and Waiver. This Agreement may be amended, supplemented, or
otherwise modified only by means of a written instrument signed by both Parties. Any waiver of any rights or failure to act in a specific instance shall relate only to such instance and shall not be construed as an agreement to waive any rights or
fail to act in any other instance, whether or not similar. 
 15.5 Severability. In the event that any provision of this Agreement
shall be held invalid or unenforceable for any reason, such invalidity or unenforceability shall not affect any other provision of this Agreement, and the Parties shall negotiate in good faith to modify the Agreement to preserve (to the extent
possible) their original intent. If the Parties fail to reach a modified agreement within [***] ([***]) days after the relevant provision is held invalid or unenforceable, then the dispute shall be resolved in accordance with the
procedures set forth in Article 14. While the dispute is pending resolution, this Agreement shall be construed as if such provision were deleted by agreement of the Parties. 

15.6 Binding Effect. This Agreement shall be binding upon and inure to the benefit of the Parties and their respective legal
representatives, successors and permitted assigns. 
 15.7 Headings. All headings are for convenience only and shall not affect the
meaning of any provision of this Agreement. 
 15.8 Amendment and Restatement; Entire Agreement. This Agreement amends and restates
in all respects the Restated Agreement. Except as provided herein, this Agreement, including the Exhibits attached hereto constitutes the entire agreement between the Parties with respect to their subject matter and supersedes all prior agreements
or understandings between the Parties relating to its subject matter, including without limitation the Restated Agreements. 
 15.9
Further Assurances. Each Party agrees to execute, acknowledge and deliver such further instructions, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 

15.10 Counterparts. This Agreement may be executed simultaneously in one or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument. For clarity, PDF signatures will be treated as original signatures. 

(remainder of this page intentionally left blank) 

  
 Confidential Portions
of this Exhibit marked as [***] have been omitted pursuant to a request for 
 confidential treatment and have been filed separately with the
Securities and Exchange Commission. 

  
 20 

 Confidential Treatment Requested by Sienna Biopharmaceuticals, Inc. 

 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly
authorized representatives. 
  

									
	NANOCOMPOSIX, INC.	 		 	SIENNA BIOPHARMACEUTICALS, INC.
					
	By:	 	 /s/ Steven Oldenburg
	 		 	By:	 	 /s/ Frederick C. Beddingfield

					
	Name:	 	Steven Oldenburg	 		 	Name:	 	Frederick C. Beddingfield
					
	Title:	 	President	 		 	Title:	 	President and Chief Executive Officer

 (Signature page to the Amended and Restated Exclusive Supply and License Agreement) 

  
 Confidential Portions
of this Exhibit marked as [***] have been omitted pursuant to a request for 
 confidential treatment and have been filed separately with the
Securities and Exchange Commission. 

 Confidential Treatment Requested by Sienna Biopharmaceuticals, Inc. 

 

 EXHIBIT A 

MATERIALS 
 [***].

  
 Confidential Portions
of this Exhibit marked as [***] have been omitted pursuant to a request for 
 confidential treatment and have been filed separately with the
Securities and Exchange Commission. 

 Confidential Treatment Requested by Sienna Biopharmaceuticals, Inc. 

 

 EXHIBIT B 

PATENT RIGHTS 

Nanocomposix Exclusively Owned Patents 
 [***]

 Jointly Owned Patents 
  

					
	 Jurisdiction
	  	 Registration / Serial

Number
	  	 Ownership

			
	[***]	  	[***]	  	Sienna Joint Ownership with Nanocomposix
			
	[***]	  	[***]	  	Sienna Joint Ownership with Nanocomposix
			
	[***]	  	[***]	  	Sienna Joint Ownership with Nanocomposix
			
	[***]	  	[***]	  	Sienna Joint Ownership with Nanocomposix
			
	[***]	  	[***]	  	Sienna Joint Ownership with Nanocomposix
			
	[***]	  	[***]	  	Sienna Joint Ownership with Nanocomposix
			
	[***]	  	[***]	  	Sienna Joint Ownership with Nanocomposix
			
	[***]	  	[***]	  	Sienna Joint Ownership with Nanocomposix
			
	[***]	  	[***]	  	Sienna Joint Ownership with Nanocomposix
			
	[***]	  	[***]	  	Sienna Joint Ownership with Nanocomposix
			
	[***]	  	[***]	  	Sienna Joint Ownership with Nanocomposix
			
	[***]	  	[***]	  	Sienna Joint Ownership with Nanocomposix
			
	[***]	  	[***]	  	Sienna Joint Ownership with Nanocomposix
			
	[***]	  	[***]	  	Sienna Joint Ownership with Nanocomposix
			
	[***]	  	[***]	  	Sienna Joint Ownership with Nanocomposix
			
	[***]	  	[***]	  	Sienna Joint Ownership with Nanocomposix

  
 Confidential Portions
of this Exhibit marked as [***] have been omitted pursuant to a request for 
 confidential treatment and have been filed separately with the
Securities and Exchange Commission. 

 Confidential Treatment Requested by Sienna Biopharmaceuticals, Inc. 

 

 EXHIBIT C 

SUPPLY TERMS 

1. Product Requirements.  
 [***]

 [***] 
 [***]

 [***] 
 [***]

 [***] 
 These
requirements may be modified upon written agreement of parties. 
 2. Pricing and Payment. 

2.1 Pricing. The following prices are for the production of Materials [***]. The Material is priced as [***]. The pricing of the
Material will be [***]. For example, [***]. After the purchase of [***], the price per OD unit will be reduced to [***]. 

2.2 Payment. For each order of the Materials, SIENNA will prepay [***] of the order price at the time of placing the order, with the
remainder due upon delivery by NANOCOMPOSIX. 
 If [***] and [***] are necessary in order for the production of the Materials to meet
[***] requirements, [***] for [***] in connection with the implementation of the [***] on a [***]. A separate agreement for this work will be negotiated by the Parties. 

3. Forecasting. SIENNA will provide NANOCOMPOSIX with [***] forecasts of its requirement for the Materials. NANOCOMPOSIX will
have [***] to deliver the Materials from the time of order and [***]% of the order cost will be paid at the time of order with the remainder paid within [***] days of delivery. 

4. Right to Obtain Materials from Other Sources. 

4.1. For Convenience. At any time, SIENNA may elect to assume the manufacturing of the Materials and [***] and secure the
transfer from NANOCOMPOSIX of [***] technology necessary for the manufacture of the Materials for a purchase price of [***] Dollars ($[***]) and NANOCOMPOSIX will grant to SIENNA and its Affiliates, and hereby grants to SIENNA
and its Affiliates, effective immediately upon such payment, [***], a royalty-free, fully-paid up, exclusive license, with the right to sublicense pursuant to Section 3.2 of the Agreement, under NANOCOMPOSIX’S rights to the
Materials, to make, have made, use, have used, sell, have sold, offer to sell, have offered for sale, import and have imported Licensed Products in the Field in the Territory. 

  
 Confidential Portions
of this Exhibit marked as [***] have been omitted pursuant to a request for 
 confidential treatment and have been filed separately with the
Securities and Exchange Commission. 

 Confidential Treatment Requested by Sienna Biopharmaceuticals, Inc. 

 

 4.2 Alternative Supplier. At any time, SIENNA may elect to qualify a secondary
supplier of the Materials (whereby SIENNA will remain obligated to purchase at least [***] percent ([***]%) of its requirements for the Materials from NANOCOMPOSIX) and [***] and secure the transfer from NANOCOMPOSIX of
[***] technology necessary for the manufacture of the Materials by such secondary supplier, in which instance the purchase price will be [***] Dollars ($[***]) and NANOCOMPOSIX will grant to SIENNA and its Affiliates, and hereby
grants to SIENNA and its Affiliates, effective immediately upon such payment, [***], a royalty-free, fully-paid up, exclusive license, with the right to sublicense pursuant to Section 3.2 of the Agreement, under NANOCOMPOSIX’S
rights to the Materials, to make, have made, use, have used, sell, have sold, offer to sell, have offered for sale, import and have imported Licensed Products in the Field in the Territory. 

4.3 Failure to Supply. If NANOCOMPOSIX [***] of the Materials ordered pursuant to the terms of this Agreement, NANOCOMPOSIX will
promptly notify SIENNA . If at any time during the term (a) such notice is received by SIENNA from NANOCOMPOSIX with respect to [***] of Materials ordered by SIENNA [***], (b) NANOCOMPOSIX makes any delivery of [***]
Materials more than [***] ([***]) days later that the required delivery date, (c) NANOCOMPOSIX’s deliveries of [***] Materials ordered by SIENNA are late in aggregate by [***] ([***]) days or more in any
[***] ([***]) day period, (d) upon [***] request by SIENNA [***], NANOCOMPOSIX fails to provide [***] of [***] to [***] to [***] as [***] of [***], or (e) NANOCOMPOSIX
supplies [***] Materials and fails to provide [***] replacement Materials within [***] ([***]) days from notification of the defect, then, SIENNA in its sole discretion shall have the right to cancel [***] existing
orders for the Materials [***] and/or to exercise SIENNA right on a going forward basis to obtain the Materials from third parties and/or manufacture the Materials itself. In this instance, NANOCOMPOSIX will provide the [***] and
transfer [***] technology necessary for the manufacture of the Materials at a [***] purchase price to be agreed by the parties, such purchase price not to exceed of [***] Dollars ($[***]), [***], and NANOCOMPOSIX
will grant to SIENNA and its Affiliates, and hereby grants to SIENNA and its Affiliates, effective immediately upon such payment, [***], a royalty-free, fully-paid up, exclusive license, with the right to sublicense pursuant to
Section 3.2 of the Agreement, under NANOCOMPOSIX’S rights to the Materials, to make, have made, use, have used, sell, have sold, offer to sell, have offered for sale, import and have imported Licensed Products in the Field in the
Territory. 
 4.4. Technology Transfer Procedures. In the event SIENNA makes the election under Section 4.1 or 4.2, or in the
event of a failure to supply under Section 4.3, NANOCOMPOSIX will promptly deliver to SIENNA then [***] and [***] relating to the Materials and the manufacture thereof, [***] to enable SIENNA or its designee to manufacture
the Materials (collectively, the “Technology Transfer”). Such Technology Transfer shall include, without limitation, [***] know-how [***] to the manufacturing process for the
Materials, such as [***], and any other knowledge, documentation and information that may be [***] for SIENNA or its designee to assume [***] manufacture of the Materials. NANOCOMPOSIX shall provide [***] assistance that
may be [***] required for SIENNA to manufacture the Materials, including without limitation [***]. NANOCOMPOSIX will make NANOCOMPOSIX personnel (or contractors) who are [***] the manufacture of the Materials available to
provide assistance to SIENNA and/or third parties designated by SIENNA. 
 4.5 Rights Outside of the Field. For clarity, exercise of
any of the rights granted to SIENNA under Sections 4.1, 4.2, 4.3, or 4.4 above will not grant SIENNA any rights or licenses to the Patent Rights, or rights to the Materials, outside of the Field. 

5. Change Management. 

5.1 During the Term, if NANOCOMPOSIX or SIENNA wish to or is required by a regulatory authority to make a change to: (i) [***];
(ii) [***]; or (iii) [***] (each a “Manufacturing Change”), it shall submit to the other Party in writing details of the requested Manufacturing Change. If NANOCOMPOSIX is the requesting Party, such proposed
change shall require the written approval by SIENNA prior to implementation. 

  
 Confidential Portions
of this Exhibit marked as [***] have been omitted pursuant to a request for 
 confidential treatment and have been filed separately with the
Securities and Exchange Commission. 

 Confidential Treatment Requested by Sienna Biopharmaceuticals, Inc. 

 

 5.2 Changes Required by Regulatory Authority [***]. For
Manufacturing Changes that are required by applicable regulations, including any requirement of a regulatory authority (“Required Changes”), the Parties shall [***] to making such Required Changes [***]. If the
Required Change is required [***], the costs of implementing such Required Change shall be [***]. At the time of such implementation, such Required Change shall become part of the Specification and/or the Master Batch Record. It is
also agreed that any regulatory filings incident to any such Required Change shall be [***]. 
 5.3 NANOCOMPOSIX Proposed
Changes. If NANOCOMPOSIX wishes to make a manufacturing change that is not a Required Change (a “Discretionary Change”), the Parties shall discuss such Discretionary Change and [***] that the Discretionary Change will
[***], NANOCOMPOSIX shall [***] such Discretionary Change. Any change [***]. Should the Discretionary Change be [***], [***] shall [***] the costs of its implementation. 

5.4 SIENNA Proposed Changes. If SIENNA wishes to make a Discretionary Change, the Parties shall discuss such Discretionary Change and,
[***], subject to [***], NANOCOMPOSIX shall implement such Discretionary Change. Unless otherwise agreed by the Parties, [***] shall [***] the costs incurred by NANOCOMPOSIX in connection with the implementation of a
discretionary change requested by SIENNA. 
 (the remainder of this page is intentionally blank) 

  
 Confidential Portions
of this Exhibit marked as [***] have been omitted pursuant to a request for 
 confidential treatment and have been filed separately with the
Securities and Exchange Commission.EX-10.6(a)

 Exhibit 10.6(a) 

SIENNA BIOPHARMACEUTICALS, INC. 

2017 INCENTIVE AWARD PLAN 

ARTICLE 1. 
 PURPOSE

 The purpose of the Sienna Biopharmaceuticals, Inc. 2017 Incentive Award Plan (as it may be amended or restated from time to time, the
“Plan”) is to promote the success and enhance the value of Sienna Biopharmaceuticals, Inc. (the “Company”) by linking the individual interests of the members of the Board, Employees, and Consultants to those of
Company stockholders and by providing such individuals with an incentive for outstanding performance to generate superior returns to Company stockholders. The Plan is further intended to provide flexibility to the Company in its ability to motivate,
attract, and retain the services of members of the Board, Employees, and Consultants upon whose judgment, interest, and special effort the successful conduct of the Company’s operation is largely dependent. 

ARTICLE 2. 
 DEFINITIONS
AND CONSTRUCTION 
 Wherever the following terms are used in the Plan they shall have the meanings specified below, unless the context
clearly indicates otherwise. The singular pronoun shall include the plural where the context so indicates. 
 2.1
“Administrator” shall mean the entity that conducts the general administration of the Plan as provided in Article 12. With reference to the duties of the Committee under the Plan which have been delegated to one or more persons
pursuant to Section 12.6, or as to which the Board has assumed, the term “Administrator” shall refer to such person(s) unless the Committee or the Board has revoked such delegation or the Board has terminated the assumption of such
duties. 
 2.2 “Applicable Accounting Standards” shall mean Generally Accepted Accounting Principles in the United States,
International Financial Reporting Standards or such other accounting principles or standards as may apply to the Company’s financial statements under United States federal securities laws from time to time. 

2.3 “Applicable Law” shall mean any applicable law, including without limitation: (a) provisions of the Code, the
Securities Act, the Exchange Act and any rules or regulations thereunder; (b) corporate, securities, tax or other laws, statutes, rules, requirements or regulations, whether federal, state, local or foreign; and (c) rules of any securities
exchange or automated quotation system on which the Shares are listed, quoted or traded. 
 2.4 “Award” shall mean an
Option, a Stock Appreciation Right, a Restricted Stock award, a Restricted Stock Unit award, an Other Stock or Cash Based Award or a Dividend Equivalent award, which may be awarded or granted under the Plan. 

 2.5 “Award Agreement” shall mean any written notice, agreement, terms and
conditions, contract or other instrument or document evidencing an Award, including through electronic medium, which shall contain such terms and conditions with respect to an Award as the Administrator shall determine consistent with the Plan. 

2.6 “Board” shall mean the Board of Directors of the Company. 

2.7 “Change in Control” shall mean and includes each of the following: 

(a) A transaction or series of transactions (other than an offering of Common Stock to the general public through a registration statement
filed with the Securities and Exchange Commission) whereby any “person” or related “group” of “persons” (as such terms are used in Sections 13(d) and 14(d)(2) of the Exchange Act) directly or indirectly acquires
beneficial ownership (within the meaning of Rules 13d-3 and 13d-5 under the Exchange Act) of securities of the Company possessing more than 50 % of the total combined voting power of the Company’s securities outstanding immediately after
such acquisition; provided, however, that the following acquisitions shall not constitute a Change in Control: (i) any acquisition by the Company or any of its Subsidiaries; (ii) any acquisition by an employee benefit plan
maintained by the Company or any of its Subsidiaries, (iii) any acquisition which complies with Sections 2.7(c)(i), 2.7(c)(ii) or 2.7(c)(iii); or (iv) in respect of an Award held by a particular Holder, any acquisition by the Holder or any
group of persons including the Holder (or any entity controlled by the Holder or any group of persons including the Holder); or 
 (b) The
Incumbent Directors cease for any reason to constitute a majority of the Board; 
 (c) The consummation by the Company (whether directly
involving the Company or indirectly involving the Company through one or more intermediaries) of (x) a merger, consolidation, reorganization, or business combination, (y) a sale or other disposition of all or substantially all of the
Company’s assets in any single transaction or series of related transactions or (z) the acquisition of assets or stock of another entity, in each case other than a transaction: 

(i) which results in the Company’s voting securities outstanding immediately before the transaction continuing to represent (either by
remaining outstanding or by being converted into voting securities of the Company or the person that, as a result of the transaction, controls, directly or indirectly, the Company or owns, directly or indirectly, all or substantially all of the
Company’s assets or otherwise succeeds to the business of the Company (the Company or such person, the “Successor Entity”)) directly or indirectly, at least a majority of the combined voting power of the Successor Entity’s
outstanding voting securities immediately after the transaction, and 
 (ii) after which no person or group beneficially owns voting
securities representing 50% or more of the combined voting power of the Successor Entity; provided, however, that no person or group shall be treated for purposes of this Section 2.7(c)(ii) as beneficially owning 50% or
more of the combined voting power of the Successor Entity solely as a result of the voting power held in the Company prior to the consummation of the transaction; and 

 (iii) after which at least a majority of the members of the board of directors (or the analogous
governing body) of the Successor Entity were Board members at the time of the Board’s approval of the execution of the initial agreement providing for such transaction; or 

(d) The date which is 10 business days prior to the completion of a liquidation or dissolution of the Company. 

Notwithstanding the foregoing, if a Change in Control constitutes a payment event with respect to any Award (or any portion of an Award) that provides for the
deferral of compensation that is subject to Section 409A, to the extent required to avoid the imposition of additional taxes under Section 409A, the transaction or event described in subsection (a), (b), (c) or (d) with respect
to such Award (or portion thereof) shall only constitute a Change in Control for purposes of the payment timing of such Award if such transaction also constitutes a “change in control event,” as defined in Treasury Regulation
Section 1.409A-3(i)(5). 
 The Administrator shall have full and final authority, which shall be exercised in its sole discretion, to determine
conclusively whether a Change in Control has occurred pursuant to the above definition, the date of the occurrence of such Change in Control and any incidental matters relating thereto; provided that any exercise of authority in conjunction with a
determination of whether a Change in Control is a “change in control event” as defined in Treasury Regulation Section 1.409A-3(i)(5) shall be consistent with such regulation. 

2.8 “Code” shall mean the Internal Revenue Code of 1986, as amended from time to time, together with the regulations and
official guidance promulgated thereunder, whether issued prior or subsequent to the grant of any Award. 
 2.9 “Committee”
shall mean the Compensation Committee of the Board, or another committee or subcommittee of the Board or the Compensation Committee of the Board described in Article 12 hereof. 

2.10 “Common Stock” shall mean the common stock of the Company, par value $0.0001 per share. 

2.11 “Company” shall have the meaning set forth in Article 1. 

2.12 “Consultant” shall mean any consultant or adviser engaged to provide services to the Company or any Subsidiary who
qualifies as a consultant or advisor under the applicable rules of the Securities and Exchange Commission for registration of shares on a Form S-8 Registration Statement. 

2.13 “Covered Employee” shall mean any Employee who is, or could become, a “covered employee” within the meaning of
Section 162(m) of the Code. 
 2.14 “Director” shall mean a member of the Board, as constituted from time to time. 

 2.15 “Director Limit” shall have the meaning set forth in Section 4.6. 

2.16 “Dividend Equivalent” shall mean a right to receive the equivalent value (in cash or Shares) of dividends paid on Shares,
awarded under Section 10.2. 
 2.17 “DRO” shall mean a “domestic relations order” as defined by the Code or
Title I of the Employee Retirement Income Security Act of 1974, as amended from time to time, or the rules thereunder. 
 2.18
“Effective Date” shall mean the day prior to the Public Trading Date. 
 2.19 “Eligible Individual” shall
mean any person who is an Employee, a Consultant or a Non-Employee Director, as determined by the Administrator. 
 2.20
“Employee” shall mean any officer or other employee (as determined in accordance with Section 3401(c) of the Code and the Treasury Regulations thereunder) of the Company or of any Subsidiary. 

2.21 “Equity Restructuring” shall mean a nonreciprocal transaction between the Company and its stockholders, such as a stock
dividend, stock split, spin-off, rights offering or recapitalization through a large, nonrecurring cash dividend, that affects the number or kind of Shares (or other securities of the Company) or the share price of Common Stock (or other securities)
and causes a change in the per-share value of the Common Stock underlying outstanding Awards. 
 2.22 “Exchange Act” shall
mean the Securities Exchange Act of 1934, as amended from time to time. 
 2.23 “Fair Market Value” shall mean, as of any
given date, the value of a Share determined as follows: 
 (a) If the Common Stock is (i) listed on any established securities exchange
(such as the New York Stock Exchange, the NASDAQ Capital Market, the NASDAQ Global Market and the NASDAQ Global Select Market), (ii) listed on any national market system or (iii) quoted or traded on any automated quotation system, its Fair
Market Value shall be the closing sales price for a Share as quoted on such exchange or system for such date or, if there is no closing sales price for a Share on the date in question, the closing sales price for a Share on the last preceding date
for which such quotation exists, as reported in The Wall Street Journal or such other source as the Administrator deems reliable; 
 (b) If
the Common Stock is not listed on an established securities exchange, national market system or automated quotation system, but the Common Stock is regularly quoted by a recognized securities dealer, its Fair Market Value shall be the mean of the
high bid and low asked prices for such date or, if there are no high bid and low asked prices for a Share on such date, the high bid and low asked prices for a Share on the last preceding date for which such information exists, as reported in The
Wall Street Journal or such other source as the Administrator deems reliable; or 

 (c) If the Common Stock is neither listed on an established securities exchange, national market
system or automated quotation system nor regularly quoted by a recognized securities dealer, its Fair Market Value shall be established by the Administrator in good faith. 

Notwithstanding the foregoing, with respect to any Award granted after the effectiveness of the Company’s registration statement relating
to its initial public offering and prior to the Public Trading Date, the Fair Market Value shall mean the initial public offering price of a Share as set forth in the Company’s final prospectus relating to its initial public offering filed with
the Securities and Exchange Commission. 
 2.24 “Greater Than 10% Stockholder” shall mean an individual then owning (within
the meaning of Section 424(d) of the Code) more than 10% of the total combined voting power of all classes of stock of the Company or any subsidiary corporation (as defined in Section 424(f) of the Code) or parent corporation thereof (as
defined in Section 424(e) of the Code). 
 2.25 “Holder” shall mean a person who has been granted an Award. 

2.26 “Incentive Stock Option” shall mean an Option that is intended to qualify as an incentive stock option and conforms to
the applicable provisions of Section 422 of the Code. 
 2.27 “Incumbent Directors’ shall mean for any period of 12
consecutive months, individuals who, at the beginning of such period, constitute the Board together with any new Director(s) (other than a Director designated by a person who shall have entered into an agreement with the Company to effect a
transaction described in Section 2.7(a) or 2.7(c)) whose election or nomination for election to the Board was approved by a vote of at least a majority (either by a specific vote or by approval of the proxy statement of the Company in which
such person is named as a nominee for Director without objection to such nomination) of the Directors then still in office who either were Directors at the beginning of the 12-month period or whose election or nomination for election was previously
so approved. No individual initially elected or nominated as a director of the Company as a result of an actual or threatened election contest with respect to Directors or as a result of any other actual or threatened solicitation of proxies by or
on behalf of any person other than the Board shall be an Incumbent Director. 
 2.28 “Non-Employee Director” shall mean a
Director of the Company who is not an Employee. 
 2.29 “Non-Employee Director Equity Compensation Policy” shall have the
meaning set forth in Section 4.6. 
 2.30 “Non-Qualified Stock Option” shall mean an Option that is not an Incentive
Stock Option or which is designated as an Incentive Stock Option but does not meet the applicable requirements of Section 422 of the Code. 

2.31 “Option” shall mean a right to purchase Shares at a specified exercise price, granted under Article 6. An Option shall be
either a Non-Qualified Stock Option or an Incentive Stock Option; provided, however, that Options granted to Non-Employee Directors and Consultants shall only be Non-Qualified Stock Options. 

 2.32 “Option Term” shall have the meaning set forth in Section 6.4. 

2.33 “Organizational Documents” shall mean, collectively, (a) the Company’s articles of incorporation, certificate
of incorporation, bylaws or other similar organizational documents relating to the creation and governance of the Company, and (b) the Committee’s charter or other similar organizational documentation relating to the creation and
governance of the Committee. 
 2.34 “Other Stock or Cash Based Award” shall mean a cash payment, cash bonus award, stock
payment, stock bonus award, performance award or incentive award that is paid in cash, Shares or a combination of both, awarded under Section 10.1. 

2.35 Performance-Based Compensation” shall mean any compensation that is intended to qualify as “performance-based
compensation” as described in Section 162(m)(4)(C) of the Code. 
 2.36 “Performance Criteria” shall mean the
criteria (and adjustments) that the Administrator selects for an Award for purposes of establishing the Performance Goal or Performance Goals for a Performance Period, determined as follows: 

(a) The Performance Criteria that shall be used to establish Performance Goals are limited to the following: (i) net earnings or losses
(either before or after one or more of the following: (A) interest, (B) taxes, (C) depreciation, (D) amortization and (E) non-cash equity-based compensation expense); (ii) gross or net sales or revenue or sales or
revenue growth; (iii) net income (either before or after taxes); (iv) adjusted net income; (v) operating earnings or profit (either before or after taxes); (vi) cash flow (including, but not limited to, operating cash flow and
free cash flow); (vii) return on assets; (viii) return on capital (or invested capital) and cost of capital; (ix) return on stockholders’ equity; (x) total stockholder return; (xi) return on sales; (xii) gross or
net profit or operating margin; (xiii) costs, reductions in costs and cost control measures; (xiv) expenses; (xv) working capital; (xvi) earnings or loss per share; (xvii) adjusted earnings or loss per share;
(xviii) price per share or dividends per share (or appreciation in and/or maintenance of such price or dividends); (xix) regulatory achievements or compliance (including, without limitation, regulatory body approval for commercialization
of a product); (xx) implementation or completion of critical projects; (xxi) market share; and (xxii) economic value, any of which may be measured either in absolute terms or as compared to any incremental increase or decrease or as
compared to results of a peer group or to market performance indicators or indices. 
 (b) The Administrator, in its sole discretion, may
provide that one or more objectively determinable adjustments shall be made to one or more of the Performance Goals. Such adjustments may include, but are not limited to, one or more of the following: (i) items related to a change in Applicable
Accounting Standards; (ii) items relating to financing activities; (iii) expenses for restructuring or productivity initiatives; (iv) other non-operating items; (v) items related to acquisitions; (vi) items attributable to
the business operations of any entity acquired by the Company during the Performance Period; (vii) items related to the sale or disposition of a business or segment of a business; (viii) items related to discontinued operations that do not
qualify as a segment of a business under Applicable Accounting Standards; (ix) items 

 
attributable to any stock dividend, stock split, combination or exchange of stock occurring during the Performance Period; (x) any other items of significant income or expense which are
determined to be appropriate adjustments; (xi) items relating to unusual or extraordinary corporate transactions, events or developments, (xii) items related to amortization of acquired intangible assets; (xiii) items that are outside
the scope of the Company’s core, on-going business activities; (xiv) items related to acquired in-process research and development; (xv) items relating to changes in tax laws; (xvi) items relating to major licensing or
partnership arrangements; (xvii) items relating to asset impairment charges; (xviii) items relating to gains or losses for litigation, arbitration and contractual settlements; (xix) items attributable to expenses incurred in
connection with a reduction in force or early retirement initiative; (xx) items relating to foreign exchange or currency transactions and/or fluctuations; or (xxi) items relating to any other unusual or nonrecurring events or changes in
Applicable Law, Applicable Accounting Standards or business conditions. For all Awards intended to qualify as Performance-Based Compensation, such determinations shall be made within the time prescribed by, and otherwise in compliance with,
Section 162(m) of the Code. 
 2.37 “Performance Goals” shall mean, for a Performance Period, one or more goals
established in writing by the Administrator for the Performance Period based upon one or more Performance Criteria. Depending on the Performance Criteria used to establish such Performance Goals, the Performance Goals may be expressed in terms of
overall Company performance or the performance of a Subsidiary, division, business unit, or an individual. The achievement of each Performance Goal shall be determined, to the extent applicable, with reference to Applicable Accounting Standards.

 2.38 “Performance Period” shall mean one or more periods of time, which may be of varying and overlapping durations, as
the Administrator may select, over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Holder’s right to, vesting of, and/or the payment in respect of, an Award. 

2.39 “Permitted Transferee” shall mean, with respect to a Holder, any “family member” of the Holder, as defined in
the General Instructions to Form S-8 Registration Statement under the Securities Act (or any successor form thereto), or any other transferee specifically approved by the Administrator after taking into account Applicable Law. 

2.40 “Plan” shall have the meaning set forth in Article 1. 

2.41 “Prior Plan” shall mean the Company’s 2010 Equity Incentive Plan, as such plan may be amended from time to time.

 2.42 “Program” shall mean any program adopted by the Administrator pursuant to the Plan containing the terms and
conditions intended to govern a specified type of Award granted under the Plan and pursuant to which such type of Award may be granted under the Plan. 

2.43 “Public Trading Date” shall mean the first date upon which Common Stock is listed (or approved for listing) upon notice
of issuance on any securities exchange or designated (or approved for designation) upon notice of issuance as a national market security on an interdealer quotation system. 

 2.44 “Restricted Stock” shall mean Common Stock awarded under Article 8 that is
subject to certain restrictions and may be subject to risk of forfeiture or repurchase. 
 2.45 “Restricted Stock Units”
shall mean the right to receive Shares awarded under Article 9. 
 2.46 “Section 409A” shall mean Section 409A of the
Code and the Department of Treasury regulations and other interpretive guidance issued thereunder, including, without limitation, any such regulations or other guidance that may be issued after the Effective Date. 

2.47 “Securities Act” shall mean the Securities Act of 1933, as amended. 

2.48 “Shares” shall mean shares of Common Stock. 

2.49 “Stock Appreciation Right” shall mean an Award entitling the Holder (or other person entitled to exercise pursuant to the
Plan) to exercise all or a specified portion thereof (to the extent then exercisable pursuant to its terms) and to receive from the Company an amount determined by multiplying the difference obtained by subtracting the exercise price per share of
such Award from the Fair Market Value on the date of exercise of such Award by the number of Shares with respect to which such Award shall have been exercised, subject to any limitations the Administrator may impose. 

2.50 “SAR Term” shall have the meaning set forth in Section 6.4. 

2.51 “Subsidiary” shall mean any entity (other than the Company), whether domestic or foreign, in an unbroken chain of
entities beginning with the Company if each of the entities other than the last entity in the unbroken chain beneficially owns, at the time of the determination, securities or interests representing at least fifty percent (50%) of the total
combined voting power of all classes of securities or interests in one of the other entities in such chain. 
 2.52 “Substitute
Award” shall mean an Award granted under the Plan in connection with a corporate transaction, such as a merger, combination, consolidation or acquisition of property or stock, in any case, upon the assumption of, or in substitution for,
outstanding equity awards previously granted by a company or other entity; provided, however, that in no event shall the term “Substitute Award” be construed to refer to an award made in connection with the cancellation and
repricing of an Option or Stock Appreciation Right. 
 2.53 “Termination of Service” shall mean: 

(a) As to a Consultant, the time when the engagement of a Holder as a Consultant to the Company or a Subsidiary is terminated for any reason,
with or without cause, including, without limitation, by resignation, discharge, death or retirement, but excluding terminations where the Consultant simultaneously commences or remains in employment or service with the Company or any Subsidiary.

 (b) As to a Non-Employee Director, the time when a Holder who is a Non-Employee Director ceases
to be a Director for any reason, including, without limitation, a termination by resignation, failure to be elected, death or retirement, but excluding terminations where the Holder simultaneously commences or remains in employment or service with
the Company or any Subsidiary. 
 (c) As to an Employee, the time when the employee-employer relationship between a Holder and the Company or
any Subsidiary is terminated for any reason, including, without limitation, a termination by resignation, discharge, death, disability or retirement; but excluding terminations where the Holder simultaneously commences or remains in employment or
service with the Company or any Subsidiary. 
 The Administrator, in its sole discretion, shall determine the effect of all matters and
questions relating to any Termination of Service, including, without limitation, whether a Termination of Service has occurred, whether a Termination of Service resulted from a discharge for cause and all questions of whether particular leaves of
absence constitute a Termination of Service; provided, however, that, with respect to Incentive Stock Options, unless the Administrator otherwise provides in the terms of any Program, Award Agreement or otherwise, or as otherwise
required by Applicable Law, a leave of absence, change in status from an employee to an independent contractor or other change in the employee-employer relationship shall constitute a Termination of Service only if, and to the extent that, such
leave of absence, change in status or other change interrupts employment for the purposes of Section 422(a)(2) of the Code and the then-applicable regulations and revenue rulings under said Section. For purposes of the Plan, a Holder’s
employee-employer relationship or consultancy relationship shall be deemed to be terminated in the event that the Subsidiary employing or contracting with such Holder ceases to remain an Subsidiary following any merger, sale of stock or other
corporate transaction or event (including, without limitation, a spin-off). 
 ARTICLE 3. 

SHARES SUBJECT TO THE PLAN 

3.1 Number of Shares. 

(a) Subject to Sections 13.1, 13.2 and 3.1(b), the aggregate number of Shares which may be issued or transferred pursuant to Awards under the
Plan shall be equal to the sum of (i) 1,380,155 Shares, (ii) any of the Shares which as of the Effective Date are available for issuance under the Prior Plan, or are subject to awards under the Prior Plan that, on or after the Effective
Date, terminate, expire or lapse for any reason without the delivery of Shares to the holder thereof or are repurchased by the Company at the original purchase price thereof, and (iii) an annual increase on the first day of each year beginning
in 2018 and ending in 2027 equal to the lesser of (A) four percent (4%) of the Shares outstanding (on an as converted basis) on the last day of the immediately preceding fiscal year and (B) such smaller number of Shares as determined
by the Board (such sum, the “Share Limit”); provided, however, no more than 12,000,000 Shares may be issued upon the exercise of Incentive Stock Options. Notwithstanding the foregoing, Shares added to the Share Limit pursuant to
Section 3.1(a)(ii) or Section 3.1(a)(iii) hereof shall be available for issuance as Incentive Stock Options only to the extent that making such Shares available for issuance as Incentive Stock Options would not cause any Incentive Stock
Option to cease to qualify as such. Notwithstanding the foregoing, to the extent permitted under Applicable 

 
Law, Awards that provide for the delivery of Shares subsequent to the applicable grant date may be granted in excess of the Share Limit if such Awards provide for the forfeiture or cash
settlement of such Awards to the extent that insufficient Shares remain under the Share Limit in this Section 3.1(a) at the time that Shares would otherwise be issued in respect of such Award. As of the Effective Date, no further awards may be
granted under the Prior Plan; however, any awards under the Prior Plan that are outstanding as of the Effective Date shall continue to be subject to the terms and conditions of the Prior Plan. 

(b) If any Shares subject to an Award are forfeited or expire or such Award is settled for cash (in whole or in part), the Shares subject to
such Award shall, to the extent of such forfeiture, expiration or cash settlement, again be available for future grants of Awards under the Plan. In addition, the following Shares shall be available for future grants of Awards under the Plan:
(i) Shares tendered by a Holder or withheld by the Company in payment of the exercise price of an Option or any stock option granted under the Prior Plan; (ii) Shares tendered by the Holder or withheld by the Company to satisfy any tax
withholding obligation with respect to an Award or any equity award granted under the Prior Plan; and (iii) Shares subject to Stock Appreciation Rights that are not issued in connection with the stock settlement of the Stock Appreciation Rights
on exercise thereof. Notwithstanding anything to the contrary contained herein, Shares purchased on the open market with the cash proceeds from the exercise of Options shall not be available for future grants of Awards. Any Shares repurchased by the
Company under Section 8.4 hereof at the same price paid by the Holder or a lower price so that such Shares are returned to the Company will again be available for Awards. The payment of Dividend Equivalents in cash in conjunction with any
outstanding Awards shall not be counted against the Shares available for issuance under the Plan. Notwithstanding the provisions of this Section 3.1(b), no Shares may again be optioned, granted or awarded if such action would cause an Incentive
Stock Option to fail to qualify as an incentive stock option under Section 422 of the Code. 
 (c) Substitute Awards shall not reduce
the Shares authorized for grant under the Plan, except as may be required by reason of Section 422 of the Code. Additionally, in the event that a company acquired by the Company or any Subsidiary or with which the Company or any Subsidiary
combines has shares available under a pre-existing plan approved by its stockholders and not adopted in contemplation of such acquisition or combination, the shares available for grant pursuant to the terms of such pre-existing plan (as adjusted, to
the extent appropriate, using the exchange ratio or other adjustment or valuation ratio or formula used in such acquisition or combination to determine the consideration payable to the holders of common stock of the entities party to such
acquisition or combination) may be used for Awards under the Plan and shall not reduce the Shares authorized for grant under the Plan; provided that Awards using such available Shares shall not be made after the date awards or grants could
have been made under the terms of the pre-existing plan, absent the acquisition or combination, and shall only be made to individuals who were not employed by or providing services to the Company or its Subsidiaries immediately prior to such
acquisition or combination. 

 ARTICLE 4. 

GRANTING OF AWARDS 
 4.1
Participation. The Administrator may, from time to time, select from among all Eligible Individuals, those to whom an Award shall be granted and shall determine the nature and amount of each Award, which shall not be inconsistent with the
requirements of the Plan. Except for any Non-Employee Director’s right to Awards that may be required pursuant to the Non-Employee Director Equity Compensation Policy as described in Section 4.6, no Eligible Individual or other Person
shall have any right to be granted an Award pursuant to the Plan and neither the Company nor the Administrator is obligated to treat Eligible Individuals, Holders or any other persons uniformly. Participation by each Holder in the Plan shall be
voluntary and nothing in the Plan or any Program shall be construed as mandating that any Eligible Individual or other Person shall participate in the Plan. 

4.2 Award Agreement. Each Award shall be evidenced by an Award Agreement that sets forth the terms, conditions and limitations for such
Award as determined by the Administrator in its sole discretion (consistent with the requirements of the Plan and any applicable Program). Award Agreements evidencing Awards intended to qualify as Performance-Based Compensation shall contain such
terms and conditions as may be necessary to meet the applicable provisions of Section 162(m) of the Code. Award Agreements evidencing Incentive Stock Options shall contain such terms and conditions as may be necessary to meet the applicable
provisions of Section 422 of the Code. 
 4.3 Limitations Applicable to Section 16 Persons. Notwithstanding any other
provision of the Plan, the Plan, and any Award granted or awarded to any individual who is then subject to Section 16 of the Exchange Act, shall be subject to any additional limitations set forth in any applicable exemptive rule under
Section 16 of the Exchange Act (including Rule 16b-3 of the Exchange Act and any amendments thereto) that are requirements for the application of such exemptive rule. To the extent permitted by Applicable
Law, the Plan and Awards granted or awarded hereunder shall be deemed amended to the extent necessary to conform to such applicable exemptive rule. 

4.4 At-Will Service. Nothing in the Plan or in any Program or Award Agreement hereunder shall confer upon any Holder any right to
continue in the employ of, or as a Director or Consultant for, the Company or any Subsidiary, or shall interfere with or restrict in any way the rights of the Company and any Subsidiary, which rights are hereby expressly reserved, to discharge any
Holder at any time for any reason whatsoever, with or without cause, and with or without notice, or to terminate or change all other terms and conditions of employment or engagement, except to the extent expressly provided otherwise in a written
agreement between the Holder and the Company or any Subsidiary. 
 4.5 Foreign Holders. Notwithstanding any provision of the Plan or
applicable Program to the contrary, in order to comply with the laws in countries other than the United States in which the Company and its Subsidiaries operate or have Employees, Non-Employee Directors or Consultants, or in order to comply with the
requirements of any foreign securities exchange or other Applicable Law, the Administrator, in its sole discretion, shall have the power and authority to: (a) determine which Subsidiaries shall be covered by the Plan; (b) determine which
Eligible Individuals outside the United States are eligible to participate in the Plan; (c) modify the terms and conditions of any Award granted to Eligible Individuals outside the United States to comply with Applicable Law (including, without
limitation, applicable foreign laws or 

 
listing requirements of any foreign securities exchange); (d) establish subplans and modify exercise procedures and other terms and procedures, to the extent such actions may be necessary or
advisable; provided, however, that no such subplans and/or modifications shall increase the Share Limit or the Director Limit; and (e) take any action, before or after an Award is made, that it deems advisable to obtain approval
or comply with any necessary local governmental regulatory exemptions or approvals or listing requirements of any foreign securities exchange. 

4.6 Non-Employee Director Awards. 

(a) Non-Employee Director Equity Compensation Policy. The Administrator, in its sole discretion, may provide that Awards granted to
Non-Employee Directors shall be granted pursuant to a written nondiscretionary formula established by the Administrator (the “Non-Employee Director Equity Compensation Policy”), subject to the limitations of the Plan. The
Non-Employee Director Equity Compensation Policy shall set forth the type of Award(s) to be granted to Non-Employee Directors, the number of Shares to be subject to Non-Employee Director Awards, the conditions on which such Awards shall be granted,
become exercisable and/or payable and expire, and such other terms and conditions as the Administrator shall determine in its sole discretion. The Non-Employee Director Equity Compensation Policy may be modified by the Administrator from time to
time in its sole discretion. 
 (b) Director Limit. Notwithstanding any provision to the contrary in the Plan or in the Non-Employee
Director Equity Compensation Policy, the value (determined as of the grant date in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, or any successor thereto) of cash- and equity-based Awards granted
to a Non-Employee Director as compensation for services as a Non-Employee Director during any fiscal year of the Company may not exceed $500,000 increased to $1,000,000 in the fiscal year of his or her initial service as a Non-Employee Director (the
applicable amount, the “Director Limit”). 
 ARTICLE 5. 

PROVISIONS APPLICABLE TO AWARDS INTENDED TO QUALIFY AS 

PERFORMANCE-BASED COMPENSATION 

5.1 Purpose. The Administrator may, in its sole discretion, (a) determine whether an Award is intended to qualify as
Performance-Based Compensation and (b) at any time after any such determination, alter such intent for any or no reason. If the Administrator, in its sole discretion, decides to grant an Award that is intended to qualify as Performance-Based
Compensation (other than an Option or Stock Appreciation Right), then the provisions of this Article 5 shall control over any contrary provision contained in the Plan or any applicable Program; provided that, if after such decision the
Administrator alters such intention for any reason, the provisions of this Article 5 shall no longer control over any other provision contained in the Plan or any applicable Program. The Administrator, in its sole discretion, may (i) grant
Awards to Eligible Individuals that are based on Performance Criteria or Performance Goals or any such other criteria and goals as the Administrator shall establish, but that do not satisfy the requirements of this Article 5 and that are not
intended to qualify as Performance-Based Compensation and (ii) subject any Awards intended to qualify as Performance-Based 

 
Compensation to additional conditions and restrictions unrelated to any Performance Criteria or Performance Goals (including, without limitation, continued employment or service requirements) to
the extent such Awards otherwise satisfy the requirements of this Article 5 with respect to the Performance Criteria and Performance Goals applicable thereto. Unless otherwise specified by the Administrator at the time of grant, the Performance
Criteria with respect to an Award intended to be Performance-Based Compensation payable to a Covered Employee shall be determined on the basis of Applicable Accounting Standards. 

5.2 Procedures with Respect to Performance-Based Awards. To the extent necessary to comply with the requirements of
Section 162(m)(4)(C) of the Code, with respect to any Award which is intended to qualify as Performance-Based Compensation, no later than 90 days following the commencement of any Performance Period or any designated fiscal period or period of
service (or such earlier time as may be required under Section 162(m) of the Code), the Administrator shall, in writing, (a) designate one or more Eligible Individuals, (b) select the Performance Criteria applicable to the Performance
Period, (c) establish the Performance Goals, and amounts of such Awards, as applicable, which may be earned for such Performance Period based on the Performance Criteria, and (d) specify the relationship between Performance Criteria and
the Performance Goals and the amounts of such Awards, as applicable, to be earned by each Covered Employee for such Performance Period. Following the completion of each Performance Period, the Administrator shall certify in writing whether and the
extent to which the applicable Performance Goals have been achieved for such Performance Period. In determining the amount earned under such Awards, the Administrator (i) shall, unless otherwise provided in an Award Agreement, have the right to
reduce or eliminate the amount payable at a given level of performance to take into account additional factors that the Administrator may deem relevant, including the assessment of individual or corporate performance for the Performance Period, but
(ii) shall in no event have the right to increase the amount payable for any reason. 
 5.3 Payment of Performance-Based Awards.
Unless otherwise provided in the applicable Program or Award Agreement and only to the extent otherwise permitted by Section 162(m) of the Code, as to an Award that is intended to qualify as Performance-Based Compensation, the Holder must be
employed by the Company or a Subsidiary throughout the Performance Period. Unless otherwise provided in the applicable Program or Award Agreement, a Holder shall be eligible to receive payment pursuant to such Awards for a Performance Period only if
and to the extent the Performance Goals for such Performance Period are achieved. 
 5.4 Additional Limitations. Notwithstanding any
other provision of the Plan and except as otherwise determined by the Administrator, any Award which is granted to an Eligible Individual and is intended to qualify as Performance-Based Compensation shall be subject to any additional limitations set
forth in Section 162(m) of the Code or any regulations or rulings issued thereunder that are requirements for qualification as Performance-Based Compensation, and the Plan and the applicable Program and Award Agreement shall be deemed amended
to the extent necessary to conform to such requirements. 

 ARTICLE 6. 

GRANTING OF OPTIONS AND STOCK APPRECIATION RIGHTS 

6.1 Granting of Options and Stock Appreciation Rights to Eligible Individuals. The Administrator is authorized to grant Options and
Stock Appreciation Rights to Eligible Individuals from time to time, in its sole discretion, on such terms and conditions as it may determine, which shall not be inconsistent with the Plan. 

6.2 Qualification of Incentive Stock Options. The Administrator may grant Options intended to qualify as Incentive Stock Options only to
employees of the Company, any of the Company’s present or future “parent corporations” or “subsidiary corporations” as defined in Sections 424(e) or (f) of the Code, respectively, and any other entities the employees of
which are eligible to receive Incentive Stock Options under the Code. No person who qualifies as a Greater Than 10% Stockholder may be granted an Incentive Stock Option unless such Incentive Stock Option conforms to the applicable provisions of
Section 422 of the Code. To the extent that the aggregate fair market value of stock with respect to which “incentive stock options” (within the meaning of Section 422 of the Code, but without regard to Section 422(d) of the
Code) are exercisable for the first time by a Holder during any calendar year under the Plan, and all other plans of the Company and any parent corporation or subsidiary corporation thereof (as defined in Section 424(e) and 424(f) of the Code,
respectively), exceeds $100,000, the Options shall be treated as Non-Qualified Stock Options to the extent required by Section 422 of the Code. The rule set forth in the immediately preceding sentence shall be applied by taking Options and
other “incentive stock options” into account in the order in which they were granted and the fair market value of stock shall be determined as of the time the respective options were granted. Any interpretations and rules under the Plan
with respect to Incentive Stock Options shall be consistent with the provisions of Section 422 of the Code. Neither the Company nor the Administrator shall have any liability to a Holder, or any other Person, (a) if an Option (or any part
thereof) which is intended to qualify as an Incentive Stock Option fails to qualify as an Incentive Stock Option or (b) for any action or omission by the Company or the Administrator that causes an Option not to qualify as an Incentive Stock
Option, including without limitation, the conversion of an Incentive Stock Option to a Non-Qualified Stock Option or the grant of an Option intended as an Incentive Stock Option that fails to satisfy the requirements under the Code applicable to an
Incentive Stock Option. 
 6.3 Option and Stock Appreciation Right Exercise Price. The exercise price per Share subject to each Option
and Stock Appreciation Right shall be set by the Administrator, but shall not be less than 100% of the Fair Market Value of a Share on the date the Option or Stock Appreciation Right, as applicable, is granted (or, as to Incentive Stock Options, on
the date the Option is modified, extended or renewed for purposes of Section 424(h) of the Code). In addition, in the case of Incentive Stock Options granted to a Greater Than 10% Stockholder, such price shall not be less than 110% of the Fair
Market Value of a Share on the date the Option is granted (or the date the Option is modified, extended or renewed for purposes of Section 424(h) of the Code). Notwithstanding the foregoing, in the case of an Option or Stock Appreciation Right
that is a Substitute Award, the exercise price per share of the Shares subject to such Option or Stock Appreciation Right, as applicable, may be less than the Fair Market Value per share on the date of grant; provided that the exercise price
of any Substitute Award shall be determined in accordance with the applicable requirements of Section 424 and 409A of the Code. 

 6.4 Option and SAR Term. The term of each Option (the “Option Term”) and
the term of each Stock Appreciation Right (the “SAR Term”) shall be set by the Administrator in its sole discretion; provided, however, that the Option Term or SAR Term, as applicable, shall not be more than
(a) ten (10) years from the date the Option or Stock Appreciation Right, as applicable, is granted to an Eligible Individual (other than a Greater Than 10% Stockholder), or (b) five (5) years from the date an Incentive Stock
Option is granted to a Greater Than 10% Stockholder. Except as limited by the requirements of Section 409A or Section 422 of the Code and regulations and rulings thereunder or the first sentence of this Section 6.4 and without
limiting the Company’s rights under Section 11.7, the Administrator may extend the Option Term of any outstanding Option or the SAR Term of any outstanding Stock Appreciation Right, and may extend the time period during which vested
Options or Stock Appreciation Rights may be exercised, in connection with any Termination of Service of the Holder or otherwise, and may amend, subject to Section 11.7 and 13.1, any other term or condition of such Option or Stock Appreciation
Right relating to such Termination of Service of the Holder or otherwise. 
 6.5 Option and SAR Vesting. The period during which the
right to exercise, in whole or in part, an Option or Stock Appreciation Right vests in the Holder shall be set by the Administrator and set forth in the applicable Award Agreement. Unless otherwise determined by the Administrator in the Award
Agreement, the applicable Program or by action of the Administrator following the grant of the Option or Stock Appreciation Right, (a) no portion of an Option or Stock Appreciation Right which is unexercisable at a Holder’s Termination of
Service shall thereafter become exercisable and (b) the portion of an Option or Stock Appreciation Right that is unexercisable at a Holder’s Termination of Service shall automatically expire on the date of such Termination of Service. 

6.6 Substitution of Stock Appreciation Rights. The Administrator may provide in the applicable Program or Award Agreement evidencing the
grant of an Option that the Administrator, in its sole discretion, shall have the right to substitute a Stock Appreciation Right for such Option at any time prior to or upon exercise of such Option; provided that such Stock Appreciation Right
shall be exercisable with respect to the same number of Shares for which such substituted Option would have been exercisable, and shall also have the same exercise price, vesting schedule and remaining term as the substituted Option. 

ARTICLE 7. 
 EXERCISE OF
OPTIONS AND STOCK APPRECIATION RIGHTS 
 7.1 Exercise and Payment. An exercisable Option or Stock Appreciation Right may be
exercised in whole or in part. However, an Option or Stock Appreciation Right shall not be exercisable with respect to fractional Shares and the Administrator may require that, by the terms of the Option or Stock Appreciation Right, a partial
exercise must be with respect to a minimum number of Shares. Payment of the amounts payable with respect to Stock Appreciation Rights pursuant to this Article 7 shall be in cash, Shares (based on its Fair Market Value as of the date the Stock
Appreciation Right is exercised), or a combination of both, as determined by the Administrator. 

 7.2 Manner of Exercise. Except as set forth in Section 7.3, all or a portion of an
exercisable Option or Stock Appreciation Right shall be deemed exercised upon delivery of all of the following to the Secretary of the Company, the stock plan administrator of the Company or such other person or entity designated by the
Administrator, or his, her or its office, as applicable: 
 (a) A written or electronic notice complying with the applicable rules
established by the Administrator stating that the Option or Stock Appreciation Right, or a portion thereof, is exercised. The notice shall be signed or otherwise acknowledged electronically by the Holder or other person then entitled to exercise the
Option or Stock Appreciation Right or such portion thereof; 
 (b) Such representations and documents as the Administrator, in its sole
discretion, deems necessary or advisable to effect compliance with Applicable Law. 
 (c) In the event that the Option shall be exercised
pursuant to Section 11.3 by any person or persons other than the Holder, appropriate proof of the right of such person or persons to exercise the Option or Stock Appreciation Right, as determined in the sole discretion of the Administrator; and

 (d) Full payment of the exercise price and applicable withholding taxes for the Shares with respect to which the Option or Stock
Appreciation Right, or portion thereof, is exercised, in a manner permitted by the Administrator in accordance with Sections 11.1 and 11.2. 

7.3 Notification Regarding Disposition. The Holder shall give the Company prompt written or electronic notice of any disposition of
Shares acquired by exercise of an Incentive Stock Option which occurs within (a) two years from the date of grant (including the date the Option is modified, extended or renewed for purposes of Section 424(h) of the Code) such Option to
such Holder, or (b) one year after the date of transfer of such Shares to such Holder. Such notice shall specify the date of such disposition or other transfer and the amount realized, in cash, other property, assumption of indebtedness or
other consideration, by the Holder in such disposition or other transfer. 
 ARTICLE 8. 

AWARD OF RESTRICTED STOCK 

8.1 Award of Restricted Stock. The Administrator is authorized to grant Restricted Stock to Eligible Individuals, and shall determine
the terms and conditions, including the restrictions applicable to each award of Restricted Stock, which terms and conditions shall not be inconsistent with the Plan or any applicable Program, and may impose such conditions on the issuance of such
Restricted Stock as it deems appropriate. The Administrator shall establish the purchase price, if any, and form of payment for Restricted Stock; provided, however, that if a 

 
purchase price is charged, such purchase price shall be no less than the par value, if any, of the Shares to be purchased, unless otherwise permitted by Applicable Law. In all cases, legal
consideration shall be required for each issuance of Restricted Stock to the extent required by Applicable Law. 
 8.2 Rights as
Stockholders. Subject to Section 8.4, upon issuance of Restricted Stock, the Holder shall have, unless otherwise provided by the Administrator, all the rights of a stockholder with respect to said Shares, subject to the restrictions in the
Plan, any applicable Program and/or the applicable Award Agreement, including the right to receive all dividends and other distributions paid or made with respect to the Shares to the extent such dividends and other distributions have a record date
that is on or after the date on which the Holder to whom such Restricted Stock are granted becomes the record holder of such Restricted Stock; provided, however, that, in the sole discretion of the Administrator, any extraordinary
distributions with respect to the Shares may be subject to the restrictions set forth in Section 8.3. In addition, with respect to a share of Restricted Stock with performance-based vesting, dividends which are paid prior to vesting shall only
be paid out to the Holder to the extent that the performance-based vesting conditions are subsequently satisfied and the share of Restricted Stock vests. 

8.3 Restrictions. All shares of Restricted Stock (including any shares received by Holders thereof with respect to shares of Restricted
Stock as a result of stock dividends, stock splits or any other form of recapitalization) shall be subject to such restrictions and vesting requirements as the Administrator shall provide in the applicable Program or Award Agreement. By action taken
after the Restricted Stock is issued, the Administrator may, on such terms and conditions as it may determine to be appropriate, accelerate the vesting of such Restricted Stock by removing any or all of the restrictions imposed by the terms of the
applicable Program or Award Agreement. 
 8.4 Repurchase or Forfeiture of Restricted Stock. Except as otherwise determined by the
Administrator, if no price was paid by the Holder for the Restricted Stock, upon a Termination of Service during the applicable restriction period, the Holder’s rights in unvested Restricted Stock then subject to restrictions shall lapse, and
such Restricted Stock shall be surrendered to the Company and cancelled without consideration on the date of such Termination of Service. If a price was paid by the Holder for the Restricted Stock, upon a Termination of Service during the applicable
restriction period, the Company shall have the right to repurchase from the Holder the unvested Restricted Stock then subject to restrictions at a cash price per share equal to the price paid by the Holder for such Restricted Stock or such other
amount as may be specified in the applicable Program or Award Agreement. Notwithstanding the foregoing, the Administrator, in its sole discretion, may provide that upon certain events, including, without limitation, a Change in Control, the
Holder’s death, retirement or disability or any other specified Termination of Service or any other event, the Holder’s rights in unvested Restricted Stock then subject to restrictions shall not lapse, such Restricted Stock shall vest and
cease to be forfeitable and, if applicable, the Company shall cease to have a right of repurchase. 
 8.5 Section 83(b) Election.
If a Holder makes an election under Section 83(b) of the Code to be taxed with respect to the Restricted Stock as of the date of transfer of the Restricted Stock rather than as of the date or dates upon which the Holder would otherwise be
taxable under Section 83(a) of the Code, the Holder shall be required to deliver a copy of such election to the Company promptly after filing such election with the Internal Revenue Service along with proof of the timely filing thereof with the
Internal Revenue Service. 

 ARTICLE 9. 

AWARD OF RESTRICTED STOCK UNITS 

9.1 Grant of Restricted Stock Units. The Administrator is authorized to grant Awards of Restricted Stock Units to any Eligible
Individual selected by the Administrator in such amounts and subject to such terms and conditions as determined by the Administrator. 
 9.2
Vesting of Restricted Stock Units. At the time of grant, the Administrator shall specify the date or dates on which the Restricted Stock Units shall become fully vested and nonforfeitable, and may specify such conditions to vesting as it
deems appropriate, including, without limitation, vesting based upon the Holder’s duration of service to the Company or any Subsidiary, one or more Performance Criteria, Company performance, individual performance or other specific criteria, in
each case on a specified date or dates or over any period or periods, as determined by the Administrator. 
 9.3 Settlement and
Payment. At the time of grant, the Administrator shall specify the settlement date applicable to each grant of Restricted Stock Units, which shall be no earlier than the vesting date or dates of the Award and may be determined at the election of
the Holder (if permitted by the applicable Award Agreement); provided that, except as otherwise determined by the Administrator, and subject to compliance with Section 409A, in no event shall the settlement date relating to each
Restricted Stock Unit occur following the later of (a) the 15th day of the third month following the end of calendar year in which the applicable portion of the Restricted Stock Unit vests;
or (b) the 15th day of the third month following the end of the Company’s fiscal year in which the applicable portion of the Restricted Stock Unit vests. On the settlement date, the
Company shall, in accordance with the applicable Award Agreement and subject to Section 11.4(f), transfer to the Holder one unrestricted, fully transferable Share for each Restricted Stock Unit scheduled to be paid out on such date and not
previously forfeited, or in the sole discretion of the Administrator, an amount in cash equal to the Fair Market Value of such Shares on the settlement date or a combination of cash and Common Stock as determined by the Administrator. 

9.4 Settlement upon Termination of Service. An Award of Restricted Stock Units shall only vest and be settled while the Holder is an
Employee, a Consultant or a member of the Board, as applicable; provided, however, that the Administrator, in its sole discretion, may provide (in an Award Agreement or otherwise) that a Restricted Stock Unit award may vest and be
settled subsequent to a Termination of Service in certain events, including a Change in Control, the Holder’s death, retirement or disability or any other specified Termination of Service. 

 ARTICLE 10. 

AWARD OF OTHER STOCK OR CASH BASED AWARDS AND DIVIDEND 

EQUIVALENTS 
 10.1 Other
Stock or Cash Based Awards. The Administrator is authorized to (a) grant Other Stock or Cash Based Awards, including awards entitling a Holder to receive Shares or cash to be delivered immediately or in the future, to any Eligible
Individual and (b) determine whether such Other Stock or Cash Based Awards shall be Performance-Based Compensation. Subject to the provisions of the Plan and any applicable Program, the Administrator shall determine the terms and conditions of
each Other Stock or Cash Based Award, including the term of the Award, any exercise or purchase price, performance goals, including the Performance Criteria, transfer restrictions, vesting conditions and other terms and conditions applicable
thereto, which shall be set forth in the applicable Award Agreement. Other Stock or Cash Based Awards may be paid in cash, Shares, or a combination of cash and Shares, as determined by the Administrator, and may be available as a form of payment in
the settlement of other Awards granted under the Plan, as stand-alone payments, as a part of a bonus, deferred bonus, deferred compensation or other arrangement, and/or as payment in lieu of compensation to which an Eligible Individual is otherwise
entitled. 
 10.2 Dividend Equivalents. Dividend Equivalents may be granted by the Administrator, either alone or in tandem with
another Award, based on dividends declared on the Common Stock, to be credited as of dividend payment dates during the period between the date the Dividend Equivalents are granted to a Holder and the date such Dividend Equivalents terminate or
expire, as determined by the Administrator. Such Dividend Equivalents shall be converted to cash or additional Shares by such formula and at such time and subject to such restrictions and limitations as may be determined by the Administrator. In
addition, Dividend Equivalents with respect to an Award with performance-based vesting that are based on dividends paid prior to the vesting of such Award shall only be paid out to the Holder to the extent that the performance-based vesting
conditions are subsequently satisfied and the Award vests.Notwithstanding the foregoing, no Dividend Equivalents shall be payable with respect to Options or Stock Appreciation Rights. 

ARTICLE 11. 
 ADDITIONAL
TERMS OF AWARDS 
 11.1 Payment. The Administrator shall determine the method or methods by which payments by any Holder with
respect to any Awards granted under the Plan shall be made, including, without limitation: (a) cash or check, (b) Shares (including, in the case of payment of the exercise price of an Award, Shares issuable pursuant to the exercise of the
Award) or Shares held for such minimum period of time as may be established by the Administrator, in each case, having a Fair Market Value on the date of delivery equal to the aggregate payments required, (c) delivery of a written or electronic
notice that the Holder has placed a market sell order with a broker acceptable to the Company with respect to Shares then issuable upon exercise or vesting of an Award, and that the broker has been directed to pay a sufficient portion of the net
proceeds of the sale to the Company in satisfaction of the aggregate payments required; provided that 

 
payment of such proceeds is then made to the Company upon settlement of such sale, (d) other form of legal consideration acceptable to the Administrator in its sole discretion, or
(e) any combination of the above permitted forms of payment. Notwithstanding any other provision of the Plan to the contrary, no Holder who is a Director or an “executive officer” of the Company within the meaning of
Section 13(k) of the Exchange Act shall be permitted to make payment with respect to any Awards granted under the Plan, or continue any extension of credit with respect to such payment, with a loan from the Company or a loan arranged by the
Company in violation of Section 13(k) of the Exchange Act. 
 11.2 Tax Withholding. The Company or any Subsidiary shall have the
authority and the right to deduct or withhold, or require a Holder to remit to the Company, an amount sufficient to satisfy federal, state, local and foreign taxes (including the Holder’s FICA, employment tax or other social security
contribution obligation) required by law to be withheld with respect to any taxable event concerning a Holder arising as a result of the Plan or any Award. The Administrator may, in its sole discretion and in satisfaction of the foregoing
requirement, allow a Holder to satisfy such obligations by any payment means described in Section 11.1 hereof, including without limitation, by allowing such Holder to have the Company or any Subsidiary withhold Shares otherwise issuable under
an Award (or allow the surrender of Shares). The number of Shares which may be so withheld or surrendered shall be limited to the number of Shares which have a fair market value on the date of withholding or repurchase no greater than the aggregate
amount of such liabilities based on the maximum statutory withholding rates for federal, state, local and foreign income tax and payroll tax purposes that are applicable to such supplemental taxable income (or such other number as would not result
in adverse financial accounting consequences for the Company or any of its Subsidiaries). The Administrator shall determine the fair market value of the Shares, consistent with applicable provisions of the Code, for tax withholding obligations due
in connection with a broker-assisted cashless Option or Stock Appreciation Right exercise involving the sale of Shares to pay the Option or Stock Appreciation Right exercise price or any tax withholding obligation. 

11.3 Transferability of Awards. 

(a) Except as otherwise provided in Sections 11.3(b) and 11.3(c): 

(i) No Award under the Plan may be sold, pledged, assigned or transferred in any manner other than (A) by will or the laws of descent and
distribution or (B) subject to the consent of the Administrator, pursuant to a DRO, unless and until such Award has been exercised or the Shares underlying such Award have been issued, and all restrictions applicable to such Shares have lapsed;

 (ii) No Award or interest or right therein shall be liable for or otherwise subject to the debts, contracts or engagements of the Holder
or the Holder’s successors in interest or shall be subject to disposition by transfer, alienation, anticipation, pledge, hypothecation, encumbrance, assignment or any other means whether such disposition be voluntary or involuntary or by
operation of law by judgment, levy, attachment, garnishment or any other legal or equitable proceedings (including bankruptcy) unless and until such Award has been exercised, or the Shares underlying such Award have been issued, and all restrictions
applicable to such Shares have lapsed, and any attempted disposition of an Award prior to satisfaction of these conditions shall be null and void and of no effect, except to the extent that such disposition is permitted by Section 11.3(a)(i);
and 

 (iii) During the lifetime of the Holder, only the Holder may exercise any exercisable portion of
an Award granted to such Holder under the Plan, unless it has been disposed of pursuant to a DRO. After the death of the Holder, any exercisable portion of an Award may, prior to the time when such portion becomes unexercisable under the Plan or the
applicable Program or Award Agreement, be exercised by the Holder’s personal representative or by any person empowered to do so under the deceased Holder’s will or under the then-applicable laws of descent and distribution. 

(b) Notwithstanding Section 11.3(a), the Administrator, in its sole discretion, may determine to permit a Holder or a Permitted Transferee
of such Holder to transfer an Award other than an Incentive Stock Option (unless such Incentive Stock Option is intended to become a Nonqualified Stock Option) to any one or more Permitted Transferees of such Holder, subject to the following terms
and conditions: (i) an Award transferred to a Permitted Transferee shall not be assignable or transferable by the Permitted Transferee other than (A) to another Permitted Transferee of the applicable Holder or (B) by will or the laws
of descent and distribution or, subject to the consent of the Administrator, pursuant to a DRO; (ii) an Award transferred to a Permitted Transferee shall continue to be subject to all the terms and conditions of the Award as applicable to the
original Holder (other than the ability to further transfer the Award to any Person other than another Permitted Transferee of the applicable Holder); and (iii) the Holder (or transferring Permitted Transferee) and the receiving Permitted
Transferee shall execute any and all documents requested by the Administrator, including, without limitation documents to (A) confirm the status of the transferee as a Permitted Transferee, (B) satisfy any requirements for an exemption for
the transfer under Applicable Law and (C) evidence the transfer. In addition, and further notwithstanding Section 11.3(a), hereof, the Administrator, in its sole discretion, may determine to permit a Holder to transfer Incentive Stock
Options to a trust that constitutes a Permitted Transferee if, under Section 671 of the Code and other Applicable Law, the Holder is considered the sole beneficial owner of the Incentive Stock Option while it is held in the trust. 

(c) Notwithstanding Section 11.3(a), a Holder may, in the manner determined by the Administrator, designate a beneficiary to exercise the
rights of the Holder and to receive any distribution with respect to any Award upon the Holder’s death. A beneficiary, legal guardian, legal representative, or other person claiming any rights pursuant to the Plan is subject to all terms and
conditions of the Plan and any Program or Award Agreement applicable to the Holder and any additional restrictions deemed necessary or appropriate by the Administrator. If the Holder is married or a domestic partner in a domestic partnership
qualified under Applicable Law and resides in a community property state, a designation of a person other than the Holder’s spouse or domestic partner, as applicable, as the Holder’s beneficiary with respect to more than 50% of the
Holder’s interest in the Award shall not be effective without the prior written or electronic consent of the Holder’s spouse or domestic partner. If no beneficiary has been designated or survives the Holder, payment shall be made to the
person entitled thereto pursuant to the Holder’s will or the laws of descent and distribution. Subject to the foregoing, a beneficiary designation may be changed or revoked by a Holder at any time; provided that the change or revocation
is delivered in writing to the Administrator prior to the Holder’s death. 

 11.4 Conditions to Issuance of Shares. 

(a) The Administrator shall determine the methods by which Shares shall be delivered or deemed to be delivered to Holders. Notwithstanding
anything herein to the contrary, the Company shall not be required to issue or deliver any certificates or make any book entries evidencing Shares pursuant to the exercise of any Award, unless and until the Administrator has determined, with advice
of counsel, that the issuance of such Shares is in compliance with Applicable Law and the Shares are covered by an effective registration statement or applicable exemption from registration. In addition to the terms and conditions provided herein,
the Administrator may require that a Holder make such reasonable covenants, agreements and representations as the Administrator, in its sole discretion, deems advisable in order to comply with Applicable Law. 

(b) All share certificates delivered pursuant to the Plan and all Shares issued pursuant to book entry procedures are subject to any
stop-transfer orders and other restrictions as the Administrator deems necessary or advisable to comply with Applicable Law. The Administrator may place legends on any share certificate or book entry to reference restrictions applicable to the
Shares (including, without limitation, restrictions applicable to Restricted Stock). 
 (c) The Administrator shall have the right to require
any Holder to comply with any timing or other restrictions with respect to the settlement, distribution or exercise of any Award, including a window-period limitation, as may be imposed in the sole discretion of the Administrator. 

(d) No fractional Shares shall be issued and the Administrator, in its sole discretion, shall determine whether cash shall be given in lieu of
fractional Shares or whether such fractional Shares shall be eliminated by rounding down. 
 (e) The Company, in its sole discretion, may
(i) retain physical possession of any stock certificate evidencing Shares until any restrictions thereon shall have lapsed and/or (ii) require that the stock certificates evidencing such Shares be held in custody by a designated escrow
agent (which may but need not be the Company) until the restrictions thereon shall have lapsed, and that the Holder deliver a stock power, endorsed in blank, relating to such Shares. 

(f) Notwithstanding any other provision of the Plan, unless otherwise determined by the Administrator or required by Applicable Law, the
Company shall not deliver to any Holder certificates evidencing Shares issued in connection with any Award and instead such Shares shall be recorded in the books of the Company (or, as applicable, its transfer agent or stock plan administrator).

 11.5 Forfeiture and Claw-Back Provisions. All Awards (including any proceeds, gains or other economic benefit actually or
constructively received by a Holder upon any receipt or exercise of any Award or upon the receipt or resale of any Shares underlying the Award and any payments of a portion of an incentive-based bonus pool allocated to a Holder) shall be subject to
the provisions of any claw-back policy implemented by the Company, including, without limitation, any claw-back policy adopted to comply with the requirements of Applicable 

 
Law, including, without limitation, the Dodd-Frank Wall Street Reform and Consumer Protection Act and any rules or regulations promulgated thereunder, whether or not such claw-back policy was in
place at the time of grant of an Award, to the extent set forth in such claw-back policy and/or in the applicable Award Agreement. 
 11.6
Repricing. The Administrator shall, without the approval of the stockholders of the Company, have the authority to (a) amend any outstanding Option or Stock Appreciation Right to reduce its exercise price per Share, or (b) cancel
any Option or Stock Appreciation Right in exchange for cash or another Award. 
 11.7 Amendment of Awards. Subject to Applicable Law,
the Administrator may amend, modify or terminate any outstanding Award, including but not limited to, substituting therefor another Award of the same or a different type, changing the date of exercise or settlement, and converting an Incentive Stock
Option to a Non-Qualified Stock Option. The Holder’s consent to such action shall be required unless (a) the Administrator determines that the action, taking into account any related action, would not materially and adversely affect the
Holder, or (b) the change is otherwise permitted under the Plan (including, without limitation, under Section 13.2 or 13.10). 

11.8 Data Privacy. As a condition of receipt of any Award, each Holder explicitly and unambiguously consents to the collection, use and
transfer, in electronic or other form, of personal data as described in this Section 11.8 by and among, as applicable, the Company and its Subsidiaries for the exclusive purpose of implementing, administering and managing the Holder’s
participation in the Plan. The Company and its Subsidiaries may hold certain personal information about a Holder, including but not limited to, the Holder’s name, home address and telephone number, date of birth, social security or insurance
number or other identification number, salary, nationality, job title(s), any shares of stock held in the Company or any of its Subsidiaries, details of all Awards, in each case, for the purpose of implementing, managing and administering the Plan
and Awards (the “Data”). The Company and its Subsidiaries may transfer the Data amongst themselves as necessary for the purpose of implementation, administration and management of a Holder’s participation in the Plan, and the
Company and its Subsidiaries may each further transfer the Data to any third parties assisting the Company and its Subsidiaries in the implementation, administration and management of the Plan. These recipients may be located in the Holder’s
country, or elsewhere, and the Holder’s country may have different data privacy laws and protections than the recipients’ country. Through acceptance of an Award, each Holder authorizes such recipients to receive, possess, use, retain and
transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing the Holder’s participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third
party with whom the Company or any of its Subsidiaries or the Holder may elect to deposit any Shares. The Data related to a Holder will be held only as long as is necessary to implement, administer, and manage the Holder’s participation in the
Plan. A Holder may, at any time, view the Data held by the Company with respect to such Holder, request additional information about the storage and processing of the Data with respect to such Holder, recommend any necessary corrections to the Data
with respect to the Holder or refuse or withdraw the consents herein in writing, in any case without cost, by contacting his or her local human resources representative. The Company may cancel Holder’s ability to participate in the Plan and, in
the Administrator’s discretion, the Holder may forfeit any outstanding Awards if the Holder refuses or withdraws his or her consents as described herein. For more information on the consequences of refusal to consent or withdrawal of consent,
Holders may contact their local human resources representative. 

 ARTICLE 12. 

ADMINISTRATION 
 12.1
Administrator. The Committee shall administer the Plan (except as otherwise permitted herein). To the extent necessary to comply with Rule 16b-3 of the Exchange Act, and with respect to Awards that are intended to be Performance-Based
Compensation, including Options and Stock Appreciation Rights, then the Committee shall take all action with respect to such Awards, and the individuals taking such action shall consist solely of two or more Non-Employee Directors, each of whom is
intended to qualify as both a “non-employee director” as defined by Rule 16b-3 of the Exchange Act or any successor rule and an “outside director” for purposes of Section 162(m) of the Code. Additionally, to the extent
required by Applicable Law, each of the individuals constituting the Committee shall be an “independent director” under the rules of any securities exchange or automated quotation system on which the Shares are listed, quoted or traded.
Notwithstanding the foregoing, any action taken by the Committee shall be valid and effective, whether or not members of the Committee at the time of such action are later determined not to have satisfied the requirements for membership set forth in
this Section 12.1 or the Organizational Documents. Except as may otherwise be provided in the Organizational Documents or as otherwise required by Applicable Law, (a) appointment of Committee members shall be effective upon acceptance of
appointment, (b) Committee members may resign at any time by delivering written or electronic notice to the Board and (c) vacancies in the Committee may only be filled by the Board. Notwithstanding the foregoing, (i) the full Board,
acting by a majority of its members in office, shall conduct the general administration of the Plan with respect to Awards granted to Non-Employee Directors and, with respect to such Awards, the terms “Administrator” as used in the Plan
shall be deemed to refer to the Board and (ii) the Board or Committee may delegate its authority hereunder to the extent permitted by Section 12.6. 

12.2 Duties and Powers of Administrator. It shall be the duty of the Administrator to conduct the general administration of the Plan in
accordance with its provisions. The Administrator shall have the power to interpret the Plan, all Programs and Award Agreements, and to adopt such rules for the administration, interpretation and application of the Plan and any Program as are not
inconsistent with the Plan, to interpret, amend or revoke any such rules and to amend the Plan or any Program or Award Agreement; provided that the rights or obligations of the Holder of the Award that is the subject of any such Program or
Award Agreement are not materially and adversely affected by such amendment, unless the consent of the Holder is obtained or such amendment is otherwise permitted under Section 11.5 or Section 13.10. In its sole discretion, the Board may
at any time and from time to time exercise any and all rights and duties of the Committee in its capacity as the Administrator under the Plan except with respect to matters which under Rule 16b-3 under the
Exchange Act or any successor rule, or Section 162(m) of the Code, or any regulations or rules issued thereunder, or the rules of any securities exchange or automated quotation system on which the Shares are listed, quoted or traded are
required to be determined in the sole discretion of the Committee. 

 12.3 Action by the Administrator. Unless otherwise established by the Board, set forth in
any Organizational Documents or as required by Applicable Law, a majority of the Administrator shall constitute a quorum and the acts of a majority of the members present at any meeting at which a quorum is present, and acts approved in writing by
all members of the Administrator in lieu of a meeting, shall be deemed the acts of the Administrator. Each member of the Administrator is entitled to, in good faith, rely or act upon any report or other information furnished to that member by any
officer or other employee of the Company or any Subsidiary, the Company’s independent certified public accountants, or any executive compensation consultant or other professional retained by the Company to assist in the administration of the
Plan. 
 12.4 Authority of Administrator. Subject to the Organizational Documents, any specific designation in the Plan and Applicable
Law, the Administrator has the exclusive power, authority and sole discretion to: 
 (a) Designate Eligible Individuals to receive Awards;

 (b) Determine the type or types of Awards to be granted to each Eligible Individual (including, without limitation, any Awards granted in
tandem with another Award granted pursuant to the Plan); 
 (c) Determine the number of Awards to be granted and the number of Shares to
which an Award will relate; 
 (d) Determine the terms and conditions of any Award granted pursuant to the Plan, including, but not limited
to, the exercise price, grant price, purchase price, any Performance Criteria or other performance criteria, any restrictions or limitations on the Award, any schedule for vesting, lapse of forfeiture restrictions or restrictions on the
exercisability of an Award, and accelerations or waivers thereof, and any provisions related to non-competition and claw-back and recapture of gain on an Award, based in each case on such considerations as the Administrator in its sole discretion
determines; 
 (e) Determine whether, to what extent, and under what circumstances an Award may be settled in, or the exercise price of an
Award may be paid in cash, Shares, other Awards, or other property, or an Award may be canceled, forfeited, or surrendered; 
 (f) Prescribe
the form of each Award Agreement, which need not be identical for each Holder; 
 (g) Decide all other matters that must be determined in
connection with an Award; 
 (h) Establish, adopt, or revise any Programs, rules and regulations as it may deem necessary or advisable to
administer the Plan; 
 (i) Interpret the terms of, and any matter arising pursuant to, the Plan, any Program or any Award Agreement; 

 (j) Make all other decisions and determinations that may be required pursuant to the Plan or as
the Administrator deems necessary or advisable to administer the Plan; and 
 (k) Accelerate wholly or partially the vesting or lapse of
restrictions of any Award or portion thereof at any time after the grant of an Award, subject to whatever terms and conditions it selects and Section 13.2. 

12.5 Decisions Binding. The Administrator’s interpretation of the Plan, any Awards granted pursuant to the Plan, any Program or any
Award Agreement and all decisions and determinations by the Administrator with respect to the Plan are final, binding and conclusive on all Persons. 

12.6 Delegation of Authority. The Board or Committee may from time to time delegate to a committee of one or more members of the Board
or one or more officers of the Company the authority to grant or amend Awards or to take other administrative actions pursuant to this Article 12; provided, however, that in no event shall an officer of the Company be delegated the
authority to grant Awards to, or amend Awards held by, the following individuals: (a) individuals who are subject to Section 16 of the Exchange Act, (b) Covered Employees with respect to Awards intended to constitute Performance Based
Compensation, or (c) officers of the Company (or Directors) to whom authority to grant or amend Awards has been delegated hereunder; provided, further, that any delegation of administrative authority shall only be permitted to the
extent it is permissible under any Organizational Documents and Applicable Law (including, without limitation, Section 162(m) of the Code). Any delegation hereunder shall be subject to the restrictions and limits that the Board or Committee
specifies at the time of such delegation or that are otherwise included in the applicable Organizational Documents, and the Board or Committee, as applicable, may at any time rescind the authority so delegated or appoint a new delegatee. At all
times, the delegatee appointed under this Section 12.6 shall serve in such capacity at the pleasure of the Board or the Committee, as applicable, and the Board or the Committee may abolish any committee at any time and re-vest in itself any
previously delegated authority. 
 ARTICLE 13. 

MISCELLANEOUS PROVISIONS 

13.1 Amendment, Suspension or Termination of the Plan. 

(a) Except as otherwise provided in Section 13.1(b), the Plan may be wholly or partially amended or otherwise modified, suspended or
terminated at any time or from time to time by the Board; provided that, except as provided in Section 11.5 and Section 13.10, no amendment, suspension or termination of the Plan shall, without the consent of the Holder, materially
and adversely affect any rights or obligations under any Award theretofore granted or awarded, unless the Award itself otherwise expressly so provides. 

(b) Notwithstanding Section 13.1(a) and except as provided in Section 13.2, the Board may not without approval of the Company’s
stockholders given within twelve (12) months before or after such action increase the Share Limit. 

 (c) No Awards may be granted or awarded during any period of suspension or after termination of
the Plan, and notwithstanding anything herein to the contrary, in no event may any Incentive Stock Option be granted under the Plan after the tenth (10th) anniversary of the earlier of
(i) the date on which the Plan was adopted by the Board or (ii) the date the Plan was approved by the Company’s stockholders. 

13.2 Changes in Common Stock or Assets of the Company, Acquisition or Liquidation of the Company and Other Corporate Events. 

(a) In the event of any stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution (other than
normal cash dividends) of Company assets to stockholders, or any other change affecting the shares of the Company’s stock or the share price of the Company’s stock other than an Equity Restructuring, the Administrator may make equitable
adjustments, if any, to reflect such change with respect to: (i) the aggregate number and kind of Shares that may be issued under the Plan (including, but not limited to, adjustments of the Share Limit and kind of Shares which may be issued
under the Plan, and adjustments of the Director Limit); (ii) the number and kind of Shares (or other securities or property) subject to outstanding Awards; (iii) the terms and conditions of any outstanding Awards (including, without
limitation, any applicable performance targets or criteria with respect thereto); (iv) the grant or exercise price per share for any outstanding Awards under the Plan; and (v) the number and kind of Shares (or other securities or property)
for which automatic grants are subsequently to be made to new and continuing Non-Employee Directors pursuant to Section 4.6. Any adjustment affecting an Award intended as Performance-Based Compensation shall be made consistent with the
requirements of Section 162(m) of the Code unless otherwise determined by the Administrator. 
 (b) In the event of any transaction or
event described in Section 13.2(a) or any unusual or nonrecurring transactions or events affecting the Company, any Subsidiary of the Company, or the financial statements of the Company or any Subsidiary, or of changes in Applicable Law or
Applicable Accounting Standards, the Administrator, in its sole discretion, and on such terms and conditions as it deems appropriate, either by the terms of the Award or by action taken prior to the occurrence of such transaction or event, is hereby
authorized to take any one or more of the following actions whenever the Administrator determines that such action is appropriate in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under
the Plan or with respect to any Award under the Plan, to facilitate such transactions or events or to give effect to such changes in Applicable Law or Applicable Accounting Standards: 

(i) To provide for the termination of any such Award in exchange for an amount of cash and/or other property with a value equal to the amount
that would have been attained upon the exercise of such Award or realization of the Holder’s rights (and, for the avoidance of doubt, if as of the date of the occurrence of the transaction or event described in this Section 13.2 the
Administrator determines in good faith that no amount would have been attained upon the exercise of such Award or realization of the Holder’s rights, then such Award may be terminated by the Company without payment); 

 (ii) To provide that such Award be assumed by the successor or survivor corporation, or a parent
or subsidiary thereof, or shall be substituted for by similar options, rights or awards covering the stock of the successor or survivor corporation, or a parent or subsidiary thereof, with appropriate adjustments as to the number and kind of shares
and applicable exercise or purchase price, in all cases, as determined by the Administrator; 
 (iii) To make adjustments in the number and
type of Shares of the Company’s stock (or other securities or property) subject to outstanding Awards, and/or in the terms and conditions of (including the grant or exercise price), and the criteria included in, outstanding Awards and Awards
which may be granted in the future; 
 (iv) To provide that such Award shall be exercisable or payable or fully vested with respect to all
Shares covered thereby, notwithstanding anything to the contrary in the Plan or the applicable Program or Award Agreement; 
 (v) To replace
such Award with other rights or property selected by the Administrator; and/or 
 (vi) To provide that the Award cannot vest, be exercised
or become payable after such event. 
 (c) In connection with the occurrence of any Equity Restructuring, and notwithstanding anything to the
contrary in Sections 13.2(a) and 13.2(b): 
 (i) The number and type of securities subject to each outstanding Award and the exercise price
or grant price thereof, if applicable, shall be equitably adjusted (and the adjustments provided under this Section 13.2(c)(i) shall be nondiscretionary and shall be final and binding on the affected Holder and the Company); and/or 

(ii) The Administrator shall make such equitable adjustments, if any, as the Administrator, in its sole discretion, may deem appropriate to
reflect such Equity Restructuring with respect to the aggregate number and kind of Shares that may be issued under the Plan (including, but not limited to, adjustments of the Share Limit and kind of Shares which may be issued under the Plan. 

(d) Notwithstanding any other provision of the Plan, in the event of a Change in Control, unless the Administrator elects to (i) terminate
an Award in exchange for cash, rights or property, or (ii) cause an Award to become fully exercisable and no longer subject to any forfeiture restrictions prior to the consummation of a Change in Control, pursuant to Section 13.2,
(A) such Award (other than any portion subject to performance-based vesting) shall continue in effect or be assumed or an equivalent Award substituted by the successor corporation or a parent or subsidiary of the successor corporation and
(B) the portion of such Award subject to performance-based vesting shall be subject to the terms and conditions of the applicable Award Agreement and, in the absence of applicable terms and conditions, the Administrator’s discretion. 

 (e) In the event that the successor corporation in a Change in Control refuses to assume or
substitute for an Award (other than any portion subject to performance-based vesting), the Administrator shall cause such Award to become fully vested and, if applicable, exercisable immediately prior to the consummation of such transaction and all
forfeiture restrictions on such Award to lapse and, to the extent unexercised upon the consummation of such transaction, to terminate in exchange for cash, rights or other property pursuant to Section 13.2(b)(i). The Administrator shall notify
the Holder of any Award that becomes exercisable pursuant to the preceding sentence that such Award shall be fully exercisable for a period of fifteen (15) days from the date of such notice, contingent upon the occurrence of the Change in
Control, and such Award shall terminate upon the consummation of the Change in Control in accordance with the preceding sentence. 
 (f) For
the purposes of this Section 13.2, an Award shall be considered assumed if, following the Change in Control, the Award confers the right to purchase or receive, for each Share subject to the Award immediately prior to the Change in Control, the
consideration (whether stock, cash, or other securities or property) received in the Change in Control by holders of Common Stock for each Share held on the effective date of the transaction (and if holders were offered a choice of consideration,
the type of consideration chosen by the holders of a majority of the outstanding Shares); provided, however, that if such consideration received in the Change in Control was not solely common stock of the successor corporation or its
parent, the Administrator may, with the consent of the successor corporation, provide for the consideration to be received upon the exercise of the Award, for each Share subject to an Award, to be solely common stock of the successor corporation or
its parent equal in fair market value to the per-share consideration received by holders of Common Stock in the Change in Control. 
 (g) The
Administrator, in its sole discretion, may include such further provisions and limitations in any Award, agreement or certificate, as it may deem equitable and in the best interests of the Company that are not inconsistent with the provisions of the
Plan. 
 (h) Unless otherwise determined by the Administrator, no adjustment or action described in this Section 13.2 or in any other
provision of the Plan shall be authorized to the extent it would (i) with respect to Awards which are granted to Covered Employees and are intended to qualify as Performance-Based Compensation, cause such Award to fail to so qualify as
Performance-Based Compensation, (ii) cause the Plan to violate Section 422(b)(1) of the Code, (iii) result in short-swing profits liability under Section 16 of the Exchange Act or violate the exemptive conditions of Rule 16b-3 of
the Exchange Act, or (iv) cause an Award to fail to be exempt from or comply with Section 409A. 
 (i) The existence of the Plan,
any Program, any Award Agreement and/or the Awards granted hereunder shall not affect or restrict in any way the right or power of the Company or the stockholders of the Company to make or authorize any adjustment, recapitalization, reorganization
or other change in the Company’s capital structure or its business, any merger or consolidation of the Company, any issue of stock or of options, warrants or rights to purchase stock or of bonds, debentures, preferred or prior preference stocks
whose rights are superior to or affect the Common Stock or the rights thereof or which are convertible into or exchangeable for Common Stock, or the dissolution or liquidation of the Company, or any sale or transfer of all or any part of its assets
or business, or any other corporate act or proceeding, whether of a similar character or otherwise. 

 (j) In the event of any pending stock dividend, stock split, combination or exchange of shares,
merger, consolidation or other distribution (other than normal cash dividends) of Company assets to stockholders, or any other change affecting the Shares or the share price of the Common Stock including any Equity Restructuring, for reasons of
administrative convenience, the Company, in its sole discretion, may refuse to permit the exercise of any Award during a period of up to thirty (30) days prior to the consummation of any such transaction. 

13.3 Approval of Plan by Stockholders. The Plan shall be submitted for the approval of the Company’s stockholders within twelve
(12) months after the date of the Board’s initial adoption of the Plan. 
 13.4 No Stockholders Rights. Except as otherwise
provided herein or in an applicable Program or Award Agreement, a Holder shall have none of the rights of a stockholder with respect to Shares covered by any Award until the Holder becomes the record owner of such Shares. 

13.5 Paperless Administration. In the event that the Company establishes, for itself or using the services of a third party, an
automated system for the documentation, granting or exercise of Awards, such as a system using an internet website or interactive voice response, then the paperless documentation, granting or exercise of Awards by a Holder may be permitted through
the use of such an automated system. 
 13.6 Effect of Plan upon Other Compensation Plans. The adoption of the Plan shall not affect
any other compensation or incentive plans in effect for the Company or any Subsidiary. Nothing in the Plan shall be construed to limit the right of the Company or any Subsidiary: (a) to establish any other forms of incentives or compensation
for Employees, Directors or Consultants of the Company or any Subsidiary, or (b) to grant or assume options or other rights or awards otherwise than under the Plan in connection with any proper corporate purpose including without limitation,
the grant or assumption of options in connection with the acquisition by purchase, lease, merger, consolidation or otherwise, of the business, stock or assets of any corporation, partnership, limited liability company, firm or association. 

13.7 Compliance with Laws. The Plan, the granting and vesting of Awards under the Plan and the issuance and delivery of Shares and the
payment of money under the Plan or under Awards granted or awarded hereunder are subject to compliance with all Applicable Law (including but not limited to state, federal and foreign securities law and margin requirements), and to such approvals by
any listing, regulatory or governmental authority as may, in the opinion of counsel for the Company, be necessary or advisable in connection therewith. Any securities delivered under the Plan shall be subject to such restrictions, and the person
acquiring such securities shall, if requested by the Company, provide such assurances and representations to the Company as the Company may deem necessary or desirable to assure compliance with all Applicable Law. The Administrator, in its sole
discretion, may take whatever actions it deems necessary or appropriate to effect compliance with Applicable Law, including, without limitation, placing legends on share certificates and issuing stop-transfer notices to agents and registrars.
Notwithstanding anything to the contrary herein, the Administrator may not take any actions hereunder, and no Awards shall be granted, that would violate Applicable Law. To the extent permitted by Applicable Law, the Plan and Awards granted or
awarded hereunder shall be deemed amended to the extent necessary to conform to Applicable Law. 

 13.8 Titles and Headings, References to Sections of the Code or Exchange Act. The titles
and headings of the Sections in the Plan are for convenience of reference only and, in the event of any conflict, the text of the Plan, rather than such titles or headings, shall control. References to sections of the Code or the Exchange Act shall
include any amendment or successor thereto. 
 13.9 Governing Law. The Plan and any Programs and Award Agreements hereunder shall be
administered, interpreted and enforced under the internal laws of the State of Delaware without regard to conflicts of laws thereof or of any other jurisdiction. 

13.10 Section 409A. To the extent that the Administrator determines that any Award granted under the Plan is subject to
Section 409A, the Plan, the Program pursuant to which such Award is granted and the Award Agreement evidencing such Award shall incorporate the terms and conditions required by Section 409A. In that regard, to the extent any Award under
the Plan or any other compensatory plan or arrangement of the Company or any of its Subsidiaries is subject to Section 409A, and such Award or other amount is payable on account of a Participant’s Termination of Service (or any similarly
defined term), then (a) such Award or amount shall only be paid to the extent such Termination of Service qualifies as a “separation from service” as defined in Section 409A, and (b) if such Award or amount is payable to a
“specified employee” as defined in Section 409A then to the extent required in order to avoid a prohibited distribution under Section 409A, such Award or other compensatory payment shall not be payable prior to the earlier of
(i) the expiration of the six-month period measured from the date of the Participant’s Termination of Service, or (ii) the date of the Participant’s death. To the extent applicable, the Plan, the Program and any Award Agreements
shall be interpreted in accordance with Section 409A. Notwithstanding any provision of the Plan to the contrary, in the event that following the Effective Date the Administrator determines that any Award may be subject to Section 409A, the
Administrator may (but is not obligated to), without a Holder’s consent, adopt such amendments to the Plan and the applicable Program and Award Agreement or adopt other policies and procedures (including amendments, policies and procedures with
retroactive effect), or take any other actions, that the Administrator determines are necessary or appropriate to (A) exempt the Award from Section 409A and/or preserve the intended tax treatment of the benefits provided with respect to
the Award, or (B) comply with the requirements of Section 409A and thereby avoid the application of any penalty taxes under Section 409A. The Company makes no representations or warranties as to the tax treatment of any Award under
Section 409A or otherwise. The Company shall have no obligation under this Section 13.10 or otherwise to take any action (whether or not described herein) to avoid the imposition of taxes, penalties or interest under Section 409A with
respect to any Award and shall have no liability to any Holder or any other person if any Award, compensation or other benefits under the Plan are determined to constitute non-compliant, “nonqualified deferred compensation” subject to the
imposition of taxes, penalties and/or interest under Section 409A. 
 13.11 Unfunded Status of Awards. The Plan is intended to be
an “unfunded” plan for incentive compensation. With respect to any payments not yet made to a Holder pursuant to an Award, nothing contained in the Plan or any Program or Award Agreement shall give the Holder any rights that are greater
than those of a general creditor of the Company or any Subsidiary. 

 13.12 Indemnification. To the extent permitted under Applicable Law and the Organizational
Documents, each member of the Administrator shall be indemnified and held harmless by the Company from any loss, cost, liability, or expense that may be imposed upon or reasonably incurred by such member in connection with or resulting from any
claim, action, suit, or proceeding to which he or she may be a party or in which he or she may be involved by reason of any action or failure to act pursuant to the Plan and against and from any and all amounts paid by him or her in satisfaction of
judgment in such action, suit, or proceeding against him or her; provided he or she gives the Company an opportunity, at its own expense, to handle and defend the same before he or she undertakes to handle and defend it on his or her own
behalf. The foregoing right of indemnification shall not be exclusive of any other rights of indemnification to which such persons may be entitled pursuant to the Organizational Documents, as a matter of law, or otherwise, or any power that the
Company may have to indemnify them or hold them harmless. 
 13.13 Relationship to other Benefits. No payment pursuant to the Plan
shall be taken into account in determining any benefits under any pension, retirement, savings, profit sharing, group insurance, welfare or other benefit plan of the Company or any Subsidiary except to the extent otherwise expressly provided in
writing in such other plan or an agreement thereunder. 
 13.14 Expenses. The expenses of administering the Plan shall be borne by the
Company and its Subsidiaries. 
 * * * * * 

I hereby certify that the foregoing Plan was duly adopted by the Board of Directors of Sienna Biopharmaceuticals, Inc. on
            , 2017. 
 * * * * * 

I hereby certify that the foregoing Plan was approved by the stockholders of Sienna Biopharmaceuticals, Inc. on
            , 2017. 
 Executed on this
            day of             , 2017. 

 

	
	  

	Corporate Secretary

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00272-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00272-of-00352.parquet"}]]